CURRICULUM VITAE
Brian G. M. Durie, M.D.
Personal Information:
Current Positions
and Titles:
Birthplace:
Gullane, Scotland, UK
Citizenship:
US 1989: US Passport
British: EU Passport
Research/Corporate Office
National Program Director, Multiple Myeloma
Senior Advisor, Hematologic Malignancies
Aptium Oncology, Inc.
8201 Beverly Boulevard
Los Angeles, CA 90048
Email: bdurie@aptiumoncology.com
Telephone: (323) 966-3572
Fax: (323) 966-3685
Assistant: Christina Gomes
Email: cgomes@aptiumoncology.com
Telephone: (323) 966-3441
Cedars-Sinai Outpatient Cancer Center at the Samuel
Oschin Comprehensive Cancer Institute
Specialist in Multiple Myeloma & Related Disorders
8700 Beverly Boulevard
Los Angeles, CA 90048
Telephone: (310) 423-0702
Fax: (310) 652-8759
Patient Appointments: Kisha Poteete
Email: lpoteete@csccc.com
International Myeloma Foundation (IMF)
Chairman of the Board and International Myeloma Working
Group (IMWG)
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607
Telephone: (818) 487-7455
Fax: (818) 487-7454
Email: TheIMF@myeloma.org
Worldwide Website: http://www.myeloma.org
Assistant: Lisa Paik
Email: lpaik@myeloma.org
1
EDUCATION:
1960 - 1966
1966 - 1967
• University of Edinburgh Medical School Edinburgh,
Scotland, United Kingdom
• Royal Infirmary, University of Edinburgh, Scotland,
United Kingdom
• Medical House Officer (6 months) Wards 26 and 27
(Professor KW Donald)
Surgical Officer (6 months) Wards 7 and 8
(Professor Sir John Bruce)
1967 - 1969
• Wayne State University Medical School
Michigan, USA
Medical Resident (Professor Bing)
1969 - 1972
• Mayo Clinic, Rochester, Minnesota, USA
Medical Resident then Clinical and Research Fellow in
Hematology and Hematologic Oncology
Masters project in cellular immunology in hematologic
malignancies.
LICENSURE
1965
1966
1972
1972
1973
1993-2008
ECFMG (U.S.)
British Medical Association License (Registration: 0223285)
National Board of Medical Examiners (USA, FLEX)
Minnesota State License 0203205
Arizona State License
8048
California State License C043179
NCI INVESTIGATOR NUMBER: 10184
SPECIALTY BOARD CERTIFICATION
1972
1974
1975
Diplomate American Board of Internal Medicine (ABIM)
Diplomate ABIM Hematology
Diplomate ABIM Oncology
2
ACADEMIC APPOINTMENTS
1972 - 1973 Instructor
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
1973 - 1976 Assistant Professor of Medicine
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
1976 - 1980 Associate Professor of Medicine
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
1981 - 1992 Professor of Medicine/Hematology/Oncology
Section of Hematology and Onco0logy
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
1989 - 1992 Professor of Clinical and Laboratory Medicine/Hematology
Department of Hematology
Charing Cross and Westminster Medical School
University of London
Charing Cross Hospital
Fulham Palace Road
LONDON W6 8RF ENGLAND
1992 - 1993 Professor of Hematology/Oncology
Division of Hematology/Oncology
Cedars Sinai Medical Center
8700 Beverly Boulevard
Los Angeles, CA 90048
3
CURRENT POSITIONS
1990-Pres.
Chairman of the Board and International Myeloma Working Group
(IMWG)
International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607
Telephone:
(818) 487-7455
Fax:
(818) 487-7454
E-Mail:
TheIMF@myeloma.org
1993-Pres.
Director of Hematologic Research and Myeloma Programs
Aptium Oncology, Inc.
Cedars-Sinai Comprehensive Cancer Center
8201 Beverly Boulevard
Los Angeles, CA 90048
Telephone:
(323) 966-3572
Fax:
(323) 966-3685
Email: bdurie@aptiumoncology.com
2002-Pres.
Co-Chairman Myeloma Committee for SWOG
Southwest Oncology Group, Operations Office
14980 Omicron Drive
San Antonio, TX 78245-3217
Telephone:
(210) 677-8808
Fax:
(210) 677-0006
Website:
http://swog.org
2005-Pres.
Member of the Sutter Western Division Cancer Research Group
Independent Affiliate of Member Institution UC Davis
Alta Bates Cancer Care Center
2001 Dwight Way
Berkeley, California 94704
Telephone: 510/204-1591
Fax:
Website:
OTHER PRIOR/ONGOING APPOINTMENTS
University of Arizona
Director, Clinical Hematology
Arizona Health Sciences Center
(University of Arizona)
1979 - 1989
4
Director Fellowship Teaching Program
Clinical Cell Kinetics Service For Cancer Center
1982-86
Consultant
NIH
Review and Referral branch for cooperative group and/or R01/P01 type
grants/contracts dealing with multiple myeloma, biologic response modifiers and
drug sensitivity testing.
1975 – ongoing
MAJOR FIELDS OF CLINICAL/RESEARCH ACTIVITY
A.
Tumor Types
1. Hematologic malignancies:
Myeloma:
Hodgkin’s/non-Hodgkin’s lymphomas
acute/chronic
leukemia;
2. Selected solid tumors:
Breast carcinoma, malignant melanoma,
sarcomas, thyroid carcinoma.
B.
Research Interests
1. Investigation of basic biologic mechanisms including kinetics, genetics,
molecular biology and drug sensitivity/resistance.
2. Apply new approaches to therapy including new combination
chemotherapy regimens, new phase II agents and biologic agents, such as
VELCADE®, Thalidomide and Revlimid®.
3. New imaging techniques in myeloma including whole body MIBI, whole
body FDG/PET or CT/PET and whole body screening MRI.
4. Role of infection in pathogenesis of myeloma including bacteria and
viruses. Particular interest in “stealth viruses” and role of activated ALU type
sequences capable of retro integration.
5. Phase III clinical trials in myeloma through SWOG mechanism. Currently
P.I. for SWOG 0777 (NCT 00644228) comparing Revlimid® low dose
dexamethasone with VELCADE®/ Revlimid®/low dose dexamethasone.
5
PROFESSIONAL ACTIVITIES
TEACHING RESPONSIBILITES
Local
1972 - 1983 Medical student Hematopathology Course: Lecturer covering hematologic
malignancies, syndromes, granulocyte production and function. (Different
specific topics each year, 1972 to 1983). Approximately 100 students/class.
1983 - 1989 Overall coordinator for medical student course in Hematopathology/clinical
correlations.
1976 - 1980 Hemostasis and Thrombosis Seminars (annual) - Course 396x (Phase II
students): 1. Acquired coagulopathies; 2. Coagulation disorders in malignant
and inflammatory disease strates. Approximately 15 students.
1977 - 1989 Immunology Seminars (annual) - Course 396zz (Phase III students): 1.
Pathogenesis and approach to immunologic diseases; 2. Immune deficiency
states; 3. Abnormal immune responses (multiple myeloma, lymphomas,
leukemia, amyloidosis). Approximately 15 students.
1979
Clinical Medicine Preceptor:
Teaching, Class of 1979.
Certificate for Outstanding Preceptor Clinical
1979 - 1989 Hematology, peripheral blood and bone marrow morphology review for
Hematology/Oncology Fellows, bi-weekly.
1983 - 1992 Weekly hematology teaching conference for Hematology/Oncology fellows
(Fridays: noon).
1992 - Ong. Fellow/house staff teaching Cedars-Sinai/UCLA.
1997 - Ong. Preceptor for research fellowship rotations at Cedars-Sinai Medical Center/
UCLA in area of multiple myeloma and related disorders.
Regional
1976 - 1980 Leukemia Society of America, Arizona Chapter - Presenter at Annual
Symposia, 1976 (Phoenix), 1977 (Tucson), 1978 (Phoenix), 1979 (Tucson),
1980 (Phoenix).
6
1978
Arizona Medical Association - Chairman, Leukemia Teaching Symposia, April.
1980
Chairman for regional MKSAP-B course in Hematology.
1980
Presenter for regional MKSAP-A course in Oncology.
1987
Arizona Medical Association - Chairman, Immunoproliferative Disorders,
Teaching Symposia, May 1987.
1994
Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Myeloma Update.
1997
Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, What Causes
Myeloma?
1999
Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Plasma RNA in
Multiple Myeloma, Clinical Relevance and Molecular Pathology.
2001
Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Novel Therapies
in Multiple Myeloma.
2002
Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Role of FDG/PET
Scanning in Multiple Myeloma.
2003
Education Session, Comprehensive Cancer Center of the Desert, Palm Springs,
Novel Therapies and New Technologies in Multiple Myeloma.
2004
CME Conference, Hematologic Malignancies, Marina del Rey, CA, New
Approaches to Diagnosis and Staging for Multiple Myeloma and Related
Disorders, February 2004.
2005
CME Conference, Hematologic Malignancies, Marina del Rey, CA, New
Paradigm for Myeloma Therapy Decisions, January 2005
2006
Grand Rounds, Guidelines for Bisphosphonate Use, Miami, Fl, March 2006
CME Conference, Novel Therapies for Myeloma, Philadephia, PA, August 2006
CME Conference, Frontline Therapy for Myeloma, Rhode Island, October 2006
2007
CME Conference, New Agents for Myeloma, Los Angeles, CA, February
2007
CME Conference, Role of Transplant for Myeloma, Houston, TX, March
2007
CME Conference, Use of Freelite to Monitor Myeloma, American Association of
Clinical Pathologists, San Diego, CA, July 2007
2008
Joint HOPA/ISOPP 2008 Annual Meeting, Anaheim, CA, July 2008
7
ASH Teaching Sessions
National
American Society of Hematology Teaching Sessions
December 1977
December 1978
December 1979
December 1983
December 1984
San Diego
New Orleans
Phoenix
San Francisco
Miami
December 1985
New Orleans
December 1986
San Francisco
December 1988
San Antonio
August 1992
London
December 1992
Los Angeles
December 1996
Seattle
December 1997
San Diego
December 1999
New Orleans
December 2000
San Francisco
December 2001
Orlando
December 2002
Philadelphia
December 2003
San Diego
December 2004
San Diego
December 2005
Atlanta
December 2006
Orlando
December 2007
Atlanta
December 2008
San Francisco
Clinical application of cell kinetics
Basic concepts in multiple myeloma
Current concepts in multiple myeloma
Approaches to treatment for multiple myeloma
Organizing chairman ASH myeloma teaching
sessions
Organizing chairman ASH myeloma teaching
sessions
Organizing chairman ASH myeloma teaching
sessions
Organizing chairman ASH myeloma teaching
sessions
Organizing chairman ISH/ASH myeloma
teaching sessions
Organizing chairman ASH myeloma teaching
sessions
Chairman, Meet the professor, ASH myeloma
teaching sessions
Chairman: Brainstorming session on myeloma
research
Co-Chair Super Friday Session, New
Advances in Biology and Treatment of
myeloma
Co-Chair Super Friday Session, New
Advances in Multiple Myeloma.
Co-Chair Super Friday Session, New
Advances in Myeloma.
Coordinating/Sponsor Super Friday Session,
Challenging Cases in Multiple Myeloma.
Planning Committee Super Friday Session,
Challenging Cases in Multiple Myeloma
Chairman for Super Friday Session on
Multiple Myeloma
Chairman for Super Friday Session on
Multiple Myeloma
Chairman for Super Friday Session on
Multiple Myeloma
Chairman for Super Friday Session on
Multiple Myeloma
Scheduled chairman for Super Friday Session
on Multiple Myeloma
8
British Society of Haematology
March 1991
Glasgow
Organizing chairman BSH teaching sessions
Selected Teaching Sessions (abbreviated)
National
October 1986
Washington
The George Washington University
Medical Center. Review course in
Hematology: Plasma cell disorders session.
September 1986
Columbus
FACP course in Plasma cell disorders
September 1987
Boston
Harvard (Dana-Farber) Cancer Medicine
session on plasma cell disorders, chaired.
October 1988
Washington
The George Washington University Medical
Center. Review course in Hematology: Plasma cell
disorders session.
October 1990
Washington
The George Washington University Medical
Center. Review course in Hematology: Plasma cell
disorders session.
October 1992
Washington
The George Washington University Medical
Center. Review course in Hematology: Plasma cell
disorders session.
February 1994
Keystone
IBMTR/AABMTR Annual Symposium. Role of
autologous and allogenic transplantation in
multiple myeloma.
February 1995
Keystone
IBMTR/AABMTR Annual Symposium. Twin
transplants in multiple myeloma.
August 1996
Cleveland
Cleveland Clinic Seminar. What causes
myeloma: review and update.
October 1996
San Diego
Scripps Cancer Symposium. Current
approaches to myeloma treatment.
September 1997
Monterey
Inn at Spanish Bay. Alta Bates Symposium.
Role of high dose therapy and transplantation in
myeloma.
9
October 1998
San Diego
Scripps Cancer Symposium. Current
approaches to multiple myeloma.
January 2003
Los Angeles
Regional Meeting. Frontline Therapy of
Myeloma
April 2003
San Diego
SWOG Meeting. Analysis of Frontline
Transplant Trial
Baltimore
CMS Presentation. Role of PET/CT Imaging
In Myeloma.
June 2003
Raleigh/Durham
Regional Meeting. What Causes Myeloma?
August 2003
Atlanta
Emery Presentation.
Thalidomide/dexamethasone Therapy:
Summary Results
October 2003
Seattle
SWOG Meeting. New Imids Review
March 2004
Minneapolis
Role of DNA SNPs Analysis
April 2004
Denver
Annual Myeloma/Lymphoma Meeting: New
Approaches to Myeloma Staging
April 2004
Washington, DC
NCI/NIH: End Points Response Criteria
May 2004
Boston
June 2004
New Orleans
Review Meeting: Role of Molecular Testing
In Myeloma
ASCO: Frontline VELCADE® Therapy
July 2004
San Jose
Regional Meeting: Presenting Features of
Myeloma
October 2004
New York
Lymphoma/Myeloma Meeting: Role of
Freelite® Testing in Myeloma
Kansas City
SWOG Meeting: Molecular Testing in the
Cooperative Group Setting
November 2004
San Diego
Regional Meeting: Management of Myeloma
Bone Disease
January 2005
Las Vegas
Annual Myeloma/Lymphoma Meeting:
Prognostic Factors in Myeloma
February 2005
Dallas
Regional Meeting: Presenting Features of
Myeloma
10
March 2005
Washington DC
FDA/ODAC Meeting: Bisphosphonates and
Osteonecrosis of the Jaw
Atlanta
Regional Meeting: New Clinical Trends in
Myeloma
New York
Overview Meeting: DNA SNPs in Myeloma
Orlando
ASCO Meeting: PET Imaging in Myeloma
June 2005
Los Angeles
Regional Meeting: Frontline Therapy for
Myeloma
August 2005
Baltimore
Regional Meeting: Risk Factors for
Osteonecrosis of the Jaw
October 2005
Dallas
SWOG Meeting: New Frontline Trial Options
February 2006
San Francisco
Regional Meeting: Epidemiology of Myeloma
March 2006
Miami
Myeloma/Lymphoma Workshop: New
Approaches to Myeloma Staging
Ft. Lauderdale
Investigators Meeting: Frontline Therapy for
Myeloma
April 2006
Salt Lake City
SWOG Meeting: Phase III Protocols for
Myeloma
June 2006
Atlanta
ASCO Meeting: Role of DNA SNPs in
Myeloma
July 2006
Portland, OR
Clinical Trials Discussion: Novel Therapies
In Myeloma
October 2006
Rhode Island
Hem/Onc Specialists Regional Meeting:
Case Discussions: Treatment Options for
Myeloma
New York
Annual Lymphoma/Myeloma Meeting:
Anatomic and Functional Staging in Myeloma
December 2006
Orlando
Osteonecrosis of the Jaw Related to
Bisphosphonate Use
February 2007
Los Angeles
Bone Disease in Myeloma
March 2007
Houston
Frontline Therapy for Myeloma
May 2005
11
April 2007
Phoenix
New Clinical Trials Available in Myeloma
June 2007
Chicago
ASCO Meeting: Revlimid as Frontline Therapy
July 2007
Teaneck, NJ
Presenting Features of Myeloma
August 2007
Santa Monica
Management of Toxicities with Novel
Therapies
October 2007
Huntington Beach
SWOG Meeting: New Phase III Trials
December 2007
Atlanta
ASH Meeting: Multiple Presentations
February 2008
New York
Celgene Roadmap Meeting
March 2008
Las Vegas
Nurse Leadership Board Meeting:
Management of Novel Therapy Toxicities
April 2008
Phoenix
Role of Novel Therapy in Frontline Therapy
May 2008
Atlanta
SWOG Meeting: Revlimid/dexamethasone vs.
VELCADE/Revlimid/dexamethsone 0777
Protocol
ASCO Meeting: Lenalidomide Advisory
Board; Plerixafor
Chicago
June 2008
Anaheim
HOPA Meeting: Current Strategies to
Improve Outcomes in Myeloma
August 2008
Los Angeles
Vital Options Radio Show: New Approaches
to Myeloma Therapy
International (Selected)
1986
International Society of Hematology - Myeloma symposium:
Immunobiology of myeloma, Sydney, Australia, 1986.
1987
Italian Society of Hematology, Myeloma Symposium, Sicily, March 1987.
1987
First International Myeloma Workshop, Blenheim Palace, Oxfordshire, U.K.,
October 1987. Scientific Advisor, Keynote Speaker
1989
Second International Myeloma Workshop, Houston, Texas, U.S.A., July 1989.
Scientific Advisor/Organizing Committee, Invited Speaker
12
1990
European Myeloma Research Group (EMRG) inaugural meeting,
March 1990. (Chairman)
London,
1990
International Cancer Update: Cannes, France, November 1990.
(Chairman)
1991
Role of biologic therapy in Myeloma: Sydney, Australia, May 1991. (Chairman)
1991
Multiple Myeloma From Biology to Therapy, Third International Workshop:
Torino, Italy, April 1991. Scientific Advisor, Chairman European Committee
1992
Role of erythropoietin in treatment of Myeloma. Symposium, ISH
August 1992. Chairman, Organizing Committee
1993
Fourth International Workshop: Mayo Clinic, Rochester, Minnesota, 1993.
Scientific Advisor, Program Committee: invited speaker
1994
Multiple Myeloma, An International Perspective. The Second Clinical
Conference of the International Myeloma Foundation: The Regent Singapore,
March 1994. Organizing Chairman
1994
The demographics of multiple myeloma. Symposium, Royal College of
Physicians, London, May 1994.
1995
Fifth International Workshop on Multiple Myeloma: La Baule, France,
September 1995. Scientific Advisor, Program Committee: invited speaker
1996
Mechanisms and treatment of bone disease in myeloma. Symposium,
Vienna, Austria, September 1996.
1997
Current concepts of myeloma pathogenesis. Symposium, Sydney, Australia,
April 1997.
1997
Sixth International Workshop on Multiple Myeloma, Harvard Medical School,
Dana-Farber Cancer Institute, Boston, Massachusetts, June 1997. .Scientific
Advisor, Program Committee: invited speaker
1998
What’s new for myeloma treatment. Symposium, Toronto, Canada,
March 1998.
1998
Standard dose chemotherapy for myeloma. Symposium, Royal College
Physicians, London, July 1998.
1998
Role of viruses and retroviruses in the pathogenesis of myeloma.
Symposium, Geneva, Switzerland, September 1998.
1998
New paradigms in the management of myeloma. Symposium, Sao Paulo,
Brazil, October 1998.
13
(London),
of
1999
Seventh International Multiple Myeloma Workshop: Stockholm, Sweden,
September 1999. Scientific Advisor, Program Committee: invited speaker
2001
Eighth International Myeloma Workshop: Banff, Canada, May 2001.
Scientific Advisor, Program Committee: invited speaker
2003
Ninth International Myeloma Workshop: Salamanca, Spain, May 2003.
Scientific Advisor, Program Committee: invited speaker
2005
Eleventh International Myeloma Workshop: Sydney, Australia, April 2005.
Scientific Advisor, Program Committee: invited speaker
2006
Grand Rounds, Staging of Myeloma, Heidelberg, Germany, March 2006
CME Conference: Management of Myeloma, EHA Meeting, Amsterdam, June
2006
CME Conference: Bone Disease in Myeloma, Prague, Czech Republic,
September 2006
2007
Annual Meeting: Bone Disease in Myeloma, Paris, France, April 2007.
Anniversary Meeting: Overview of Myeloma Management, Tel Aviv, Israel, May
2007.
Role of Bisphosphonates, Vienna, Austria, EHA Meeting, June 2007.
Thirteenth International Myeloma Workshop: Response Evaluation in Myeloma,
Kos, Greece, June 2007.
Annual Investigator Meeting: Role of VELCADE® as Frontline Therapy,
Sao Paulo, Brazil, August 2007.
Investigator Meeting: Thalidomide Therapy in Myeloma, Istanbul, Turkey,
August 2007.
Annual Myeloma Meeting: Presenting Features of Myeloma, Naples, Italy,
September 2007.
Investigators Meeting: New Drugs for Myeloma, St. Petersberg, Russia,
September 2007.
Chair, First International Myeloma Symposium, Beijing, China, Multiple
Presentations, October 2007.
Myeloma Grand Rounds, Hong Kong, China, October 2007.
14
2008
Chair, International Workshop/Board Meeting: Role of Imids in Myeloma.
Torino, Italy, February 2008.
IMF Scientific Advisory Board Meeting: New Response Criteria, Bermuda, April
2008.
EHA Meeting: Durable Remission and Quality of Life in Myeloma Therapy,
Copenhagen, Denmark, June 2008.
COMMITTEES
Local
1976
Medical Service Plan Committee member, Arizona Health Sciences
Center.
1976 - 1989
Medical Ethics Review Committee member, Arizona Health Sciences
Center.
1977 - 1978
Subcommittees for Basic Laboratory Support for Planned Cancer Center
member, Arizona Health Sciences Center.
1977 - 1979
Committee (campus-wide) for Review of Recombinance DNA Research
(Biohazards Committee) member.
1977 - 1984
Radioisotope Committee member, Arizona Health Sciences Center.
1985 - 1990
Medical Staff Appeals Committee member.
1985 – 1990
Executive Committee for the University Medical Center, member.
1985 - 1990
Credentials Committee for the University Medical Center, member.
1987 - 1988
UMC Bone Marrow Transplantation Committee. Chairman.
1989 - 1992
Multiple Committees: University of London (Haematology).
1992
Hematology Research Committee: Mayo Clinic.
1992 - 2002
Bone Marrow Transplantation/Stem Cell Support Committee, CedarsSinai Medical Center, Los Angeles.
2002 - 2007
Chair: Myeloma Research Committee Cedars-Sinai Comprehensive
Cancer Center, Los Angeles.
15
Regional
1974 - 1990
Member, Leukemia Committee, Southwest Oncology Group (SWOG).
1974 - 1990
Member, Myeloma Committee, SWOG
1974 - 1990
Member, Ad Hoc Committee for Thyroid Cancer Screening (in patients
with prior head and neck irradiation) in Arizona.
1979 - 1984
Councilor for Western Section, American Federation for Clinical
Research
National and International
1976
Member NIH Ad Hoc Working Group of Hodgkin’s Disease, Lymphomas
and Plasma Cell Neoplasm (Chairman:
Daniel E. Bergsagel).
Responsible for plasma cell neoplasm’s section.
1977
Member, NCI Committee to Review Polyamines in Cancer (Chairman:
Seymour E. Cohen). Report published in Cancer Research 37:361-365,
1982.
1978
Member, Cooperative Group Basic Science Review Committee (set-up
by Cooperative Group Chairman’s Committee Chairman Dr. Barth
Hoogstraten). Basic Research, Masson Publishing, ch. 20, 361-365.
1979 - 1982
Member, Membership Committee of SWOG.
1981 - 1989
Co-chairman, Myeloma Committee for SWOG.
1983 - 1989
Chairman, Membership Committee, American Society of Hematology.
1984 - 1992
Editorial Advisory Board, Leukemia Reviews International (Marvin A.
Rich, Ed), Volume 2, Marcel Dekker, Inc.
1987 - 1992
Editorial Advisory Board, Molecular Biotherapy, the international journal
for the application of biologicals in clinical or veterinary practice.
1984 - 1992
Member, National Thyroid Cancer Study Group Committee.
1987
Member, Scientific Abstract Review Committee for the American Society
of Hematology (Dec. 1987 meeting).
1990 - Ongoing
International Medical Editorial Board. Haematology Digest.
1990 - 1993
Chairman EORTC myeloma committee (Paris).
1990 - 1993
Co-Chairman MRC myeloma committee (London).
16
1990 - 1993
Chairman EMRG (European Myeloma Research Group).
meeting, London 1990; Brussels and Torino 1991.
1990 - 1994
Chairman IMF (International Myeloma Foundation). Board of Scientific
Advisoris.
1990 - 1993
Video Journal of Oncology - New Approaches in the Diagnosis and
Treatment of Multiple Myeloma. Charing Cross Hospital (University of
London), vol. IV, No. 1.
1990 - Ongoing
Founding Executive Board Member. International Myeloma Foundation
(IMF) (October 1990).
1990 - Ongoing
Chairman, of the Executive Board, International Myeloma Foundation
(IMF) (October 1990).
1991
Chairman European Scientific Advisors for International Myeloma
Workshop, Torino, Italy, 1991.
1991 - Ongoing
Regional Editor for “FORUM.” Trends in Experimental and clinical
medicine edited by the “FORUM” for biomedical training.
1991 - 1992
Chairman, Scientific Advisory Board, Sharon Allen Leukemia Trust.
1991 - Ongoing
Member of Advisory Board of International Journal of Clinical and
Laboratory Research.
1990 - Ongoing
Medical Director, International Myeloma Foundation.
2002 - Ongoing
Co-Chairman of Myeloma Committee for Southwest Oncology Group
(SWOG)
2004 - Ongoing
Chairman of Scientific Advisor Committee for SNP Genetic Project Bank
on a Cure™
2005 - Ongoing
Member of Editorial Advisory Board of Clinical Advances in Hematology
and Oncology
2005 - Ongoing
Section Editor for Clinical Lymphoma and Myeloma
17
Inaugural
Memberships / Societies / Honors
British Medical Association (BMA)
British Society of Haematology (BSH)
British Oncology Society (BOS)
American Medical Association (AMA)
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
American Society of Cancer Research (AACR)
European Oncology Society (EOS)
Cell Kinetic Society (CKS)
American Federation for Clinical Research (AFCR)
International Society of Experimental Hematology (ISEH)
Society for Interferon Research
Mayo Alumni Association
Scholar Leukemia Society of America
Indian Journal of Hematology and Blood Transfusion, International Editorial Board
THESIS AND DISSERTATION COMMITTEES
1978
Pharmacology Ph.D. thesis Reader for Michael Rosenblum, “Distribution,
Metabolism and Excretion of Polyamines in Rats and Humans,” Graduate
College, University of Arizona.
1979
Human Genetics Ph.D. thesis Director for Debra Saxe, “Melanoma:
Chromosomal Aberrations and Their Relationship to Drug Resistance,”
Graduate College, University of Arizona.
1981
Pharmacology Ph.D. thesis Reader for Chuck Prussack, “Acetyl Polyamines
as Markers for Cancer,” Graduate College, University of Arizona.
2003
Immunology PhD thesis Reader for Ross Brown, “Molecular immunology in
multiple myeloma,” University of NSW, Sydney, Australia.
SPONSOR FOR HEMATOLOGY / ONCOLOGY FELLOWSHIPS
Maria Alma Rodriquez. Investigation of the relationship between herpes virus infections
(eg, EBV) and myeloma. Mentor for Clinical Oncology Career Development Award, 19841985.
William S. Dalton. The study of multiple drug resistance in multiple myeloma. Mentor for
Clinical Oncology Career Development Award, 1984.
Marilyn Croghan. Efficacy of biologic agents (interferon, interleukins, tumor necrosis
factors, glucocorticoids, androgens) in drug resistant myeloma. Research fellowship sponsor
1986-1988.
18
SCHOLARSHIPS AND AWARDS
1976
Scholar, Leukemia Society of America - $100,000; annual for five years.
1976
Awarded patent rights for method of high speed scintillation auto-radiography
(Patent numbers: US4 4,035,155; Canada 254,488; France 76.32880; Britain
45302/76; Germany P 26 49 902.5-52).
1979
Outstanding Preceptor Clinical Teaching
1986
Annual Hematology Research Award: Visiting Lectureship, University of Nova
Scotia, Canada.
1991
The Fifth Annual Hematologic Research Foundation Award (U.S.: New York)
Visiting Lectureship.
2003
Annual Nuclear Medicine Society Award. 1st Prize Award: Best Clinical
Medicine Study 2002. Whole body FDG/PET scanning in multiple myeloma.
2004
Honoree: International Myeloma Foundation Achievement Award, Los Angeles,
CA, November 2005
2006
Honoree: Robert A. Kyle Lifetime Achievement Award at the National Press
Club in Washington D.C., May 2006
2007
Outstanding Speaker Award, Advances in Clinical Chemistry, Education, and
New Technology, July 2008.
RESEARCH GRANTS AND FELLOWSHIPS RECEIVED
1971 - 1972 Research Scholarship Mayo Clinic (University of Minnesota). Evaluation of cell
mediated immunity (in-vitro) in patients with myelomonocytic leukemia.
1972 - 1975 Clinical Investigator Human Tumor Kinetic Center (University of Arizona). NIH
Contract NCI-C73-3717. Annual budget of $130,000.
1975 - 1978 Principal Investigator NCI-C-73-3713
Medical Oncology Program Project Grant (CA-17904)
Principal Investigator Section IIA:
Cell kinetics of multiple myeloma:
Differentiation of cell cycle phases by computerized image analysis.
Annual budget: $55,629.
1975 - 1980 Principal Investigator Section IIC (Principal Investigator - Dr. D H Russell):
Polyamines as potential markers of cancer and of the efficacy of therapy.
Annual budget: $43,373.
19
1975 - 1978 Co-investigator Section IIIC (Principal Investigator - Dr. P Bartels): Computer
analysis of human lymphocyte populations.
Annual budget: $83,146.
1975 - 1980 Co-investigator Section VA (Principal Investigator - Dr. D Huestis): Transfusion
support of patients with cancer by leukophoresis and platelet pheresis. Annual
budget: $97,164.
1976 - 1981 Research Scholar Leukemia Society of America: $100,000 for five years.
Application of rapid autoradiography and polyamine determinations in clinical
haematology/oncology.
1978 - 1982 Sister chromatid exchange and nucleolar organizer regions in peripheral blood
and bone marrow cells of patients with breast carcinoma before and after
adjuvant chemotherapy. Annual budget: $39,000.
1979 - 1980 Principal Investigator: Use of Clodronate disodium in the treatment of
hypercalcemia in patients with malignant disease. Proctor & Gamble Co.,
$64,000.
1979 - 1982 Principal Investigator: Poly (ICLC) as interferon inducer in patients with
refractory multiple myeloma (in collaboration with Arthur Levine MD, NCI).
1979 - 1984 In-vitro stem cell (blast) assay in acute myelogenous leukemia: modification
and application for cytogenetic analysis and drug sensitivity testing. Funding:
Upjohn Co., Kalamazoo, Michigan and Regional VFW grant. Total: $15,000.
1979 - 1984 Phase III evaluation of VCP ± levamisole versus VMCP-VBAP ± levamisole in
previously untreated multiple myeloma. Southwest Oncology Group Study 7927/28. Principal investigator (440 patients in study).
1980 - 1989 Multiple myeloma: kinetics, tumor markers, clonogenic assay studies. Principal
investigator POI section III C MOPP Grant CA 17904.
Total budget: $557,462 over 5 years.
1980 - 1982 Phase II evaluation of bisantrene in refractory multiple myeloma. Southwest
Oncology Group Study - 8018. Principal investigator.
1981 - 1983 Catrix studies: the efficacy of cartilage extracts against tumor cells - Lescarden,
Ltd. $85,000.
1983 - 1986 The effects of 1-25 dihydroxyvitamin D3 (and related analogs) on myeloma cell
proliferation and differentiation. Hoffman-LaRouche Inc. Principal Investigator.
1983 - 1986 Danazol: Efficacy in treatment of mild-moderate hemophilia and immune
thrombocytopenic states. Principal Investigator. Winthrop Labs, New York
(Free drug supplied for studies).
20
1984 - 1987 Evaluation of red cell polyamine levels as markers of response to
chemotherapy.
Part of polyamine project.
(Dr. DH Russell, Principal
Investigator).
1984 - 1986 Phase II evaluation of 13-cis retinoic acid in refractory multiple myeloma. Part
of Retinoid program project (Dr. F Meyskens). Principal Investigator.
1984 - 1989 Phase II evaluation of high dose cytosine arabinsoide in refractory multiple
myeloma. Principal Investigator (MOPP grant).
1984 - 1986 In-vitro evaluation of suppression of BFU-E by myeloma cells. Co-investigators:
W Walton/B Durie.
1985 - 1989 SWOG Phase III study of high dose Arac alone versus ± m-AMSA or
mitoxantrone for refractory acute myeloid leukemia or CML in blast crisis.
Principal Investigator (NCI-sponsored). Accrual 150 patients.
1986 - 1989 Trial of long-acting somatostatin analogue SMS 201-995 for malignant
carcinoid. R Rifkin / B Durie (Sandoz sponsored).
1986 - 1988 Phase II study of dexamethasone + a2 interferon in hematologic malignancies.
Principal Investigator. Schering Corporation sponsored study ($15,000).
1986 - 1989 Phase II evaluation of VAD + verapamil as treatment for refractory multiple
myeloma. B Dalton / B Durie Co-Principal Investigators.
1987 - 1989 SWOG Phase II study for primarily untreated myeloma-VMCPVBAP/VAD/VMCPP-VBAPP; a2 interferon maintenance. Principal Investigator.
NCI-sponsored. Accrual 500 patients.
1987 - 1989 Investigation of 3 new B-cell mitogens in-vitro (ORF: 21757-000; 21765-097;
22444-000).
Sponsored by Ortho Pharmaceutical Company.
Principal
Investigator.
1987 - 1989 Phase Ι-ΙΙ study of recombinant GM-CSF in neutropenic states.
sponsored study. Hersch/Durie/Salmon.
Immunex
1990 - 1993 Phase ΙΙΙ study ABCMP ± alpha interferon MRC study UK (primary induction
therapy). Co-investigator with Prof. MacLennan, Birmingham.
1991 - 1993 Phase ΙΙ study VAD ± Cyclosporin for refractory myeloma.
Investigator. EORTC study, Paris.
Principal
1994 - 1996 Phase ΙΙ study VAD + PSC 833 for refractory myeloma. Principal Investigator.
Cedars-Sinai Comprehensive Cancer Center, Los Angeles.
1998 - 2001 Phase ΙΙ study of Zoledronate for hypercalcemia. Investigator. Cedars-Sinai
Comprehensive Cancer Center, Los Angeles.
21
1998 - 2002 Phase ΙΙ study of Zoledronate for the treatment of bone disease in myeloma.
Investigator. Cedars-Sinai Comprehensive Cancer Center, Los Angeles.
2003 - 2004 Phase II study of PS-341 (Velcade) Alone and in Combination With
Dexamethasone In Previously Untreated Multiple Myeloma Patients.
Jagannath/Durie/Wolf. Salick Health Care sponsored study. Grant Support
from Millennium Pharmaceutical Co ($300,000 for treatment protocol, $50,400
for molecular studies).
2003 - 2005 An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of
Procrit® (Epoetin Alfa) In the Treatment of Anemic Cancer Patients Receiving
Chemotherapy. Protocol No. PR02-27-028. Principal Investigator for Salick
Health Care. Grant support from Ortho Biotech ($120,000).
2004 - 2006 Phase III evaluation of Thalidomide/Dexamethasone With and Without
Bortezomib (VELCADE®) in Frontline Myeloma. (S0522) A Southwest
Oncology Group (SWOG) study supported by Millennium Pharmaceuticals.
Principal Investigators: Brian G.M. Durie/Bart Barlogie. (Not Activated)
2005 – 2008 Phase II evaluation of Bortezomib (Velcade), Cytoxan, Dexamethasone, and
Thalidomide in Frontline myeloma. A Millenium Pharmaceuticals supported
study. ($600,000)
Principal Investigator: Brian G.M. Durie
2009
Phase III evaluation of Revlimid®/Dexamethasone With and Without
Bortezomib (VELCADE®) in Frontline Myeloma. (S0777) A Southwest
Oncology Group (SWOG) study supported by Millennium
Pharmaceuticals. Principal Investigators: Brian G.M. Durie/Bart
Barlogie.
22
SCIENTIFIC LECTURES AND PRESENTATIONS
1.
Durie BGM, Taswell HF: HLA antigens in myelomonocytic leukemia: Results in 50
patients. Presented at International Congress of Transfusion, Washington, DC, August,
1972.
2.
Durie BGM, Salmon SE: A new simple staging system for multiple myeloma.
Presented at the Sixty-Fourth Annual Meeting of the Proceedings of the American
Association for Cancer Research, Atlantic City, NJ, April 11-13, 1973.
3.
Sieber OF, Durie BGM, Hattler BG, Salmon SE, Fulginiti VA: Spontaneous evolution of
immune competence of Di-george syndrome. Accepted for presentation at Immunology
Session, American Pediatric Society, May 2, 1974, Washington, DC.
4.
Durie BGM, Salmon SE: High-speed scintillation (HSARG) for clinical and research
hematology. Abstract 20, p54. Presented at the Seventeenth Annual Meeting of the
American Society of Hematology, Atlanta, Georgia, December 7-10, 1974.
5.
Russell DH, Durie BGM, Salmon SE: Spermidine in the serum and urine of cancer
patients during chemotherapy as a biochemical marker of clinical response. (Abstract)
American Association for Cancer Research, Inc. Presented by Dr. Durie at the Annual
Meeting of the American Association for Cancer Research, Inc., San Diego, CA, May 810, 1975.
6.
Durie BFM, Russell DH, Salmon SE: Polyamines as predictors of success and failure in
the chemotherapy of hematologic malignancies. Gordon Research Conference, New
Hampshire, June 25, 1975.
7.
Durie BGM: Lymphoreticular disease: Review of basic concepts and clinical
evaluation. American Society of Clinical Pathology Seminar, St. Louis, MO, July 25,
1997.
8.
Durie BGM: Immunodeficiency diseases: Clinical Workshop. American Society of
Clinical Pathology National Meeting, Chicago, IL, (1) September 21, 1975.
9.
Salmon SE, Durie BGM, Alexanian R: Combination chemotherapy for multiple
myeloma. American Society of Hematology 18th Annual Meeting, Dallas, TX, 85:115,
December 1975.
10.
Durie BGM, Vaught L, Russell DH, Salmon SE: Relationship of cytokinetics to tumor
burden and response to treatment in multiple myeloma. Cell Kinetic Society, 1st Annual
Meeting, Birmingham, AL, March 1977.
11.
Durie BGM: Clinical application of cellular kinetics in hematologic malignancies.
Leukemia Society of America Symposium, Birmingham, AL, October 2, 1977.
23
12.
Durie BGM, Mundy GR, Salmon SE: Multiple myeloma, Clinical staging and role of
osteoclast-activity factor in localized bone loss. The First Scientific Evaluation
Workshop on Localized Bone Loss, Washington, DC, November 5, 1977.
13.
Salmon SE, Hamburger AW, Durie BGM: Growth, kinetics and drug sensitivity of
human myeloma stem cells. Presented at the Leukemia Society of America, Inc. 4th
Annual Memorial Symposium on Etiology and Treatment of Lymphoproliferative
Disorders, Boston, MA, April 11, 1978.
14.
Salmon SE, Durie BGM, Hamburger AW: A new basis for treatment of multiple
myeloma. Presented to the Swiss Society of Hematology, Lausanne, Switzerland, May
25, 1978.
15.
Durie BGM: Plasma cell kinetics. Yale Comprehensive Cancer Center Symposium.
New Haven, CN, October 25, 1978
16.
Durie BGM: Multiple myeloma and paraneoplastic syndromes. Eighth Annual William
Dameshek Symposium, Kansas, 1978.
17.
Durie BGM, Salmon SE: The plateau phase in multiple myeloma: A reappraisal. Blood
52(5; suppl 1):257. 21st Annual Meeting of the American Society of Hematology,
December 2-5, 1978.
18.
Durie BGM: Polyamines as biochemical markers of normal and malignant growth.
Department of Medical Oncology, St. Bartholomew’s Hospital, London, England, July
12, 1978.
19.
Durie BGM: Recent developments in multiple myeloma.
Sutton, England, July 12, 1978.
20.
Durie BGM: Kinetics of soft agar stem cell colonies. Cloning Conference, University of
Arizona Cancer Center, Tucson, Arizona, January 4, 1979.
21.
Durie BGM, Hellman D, Woolfenden J, Kartchner M, O’Mara R, Salmon SE:
Multimodality treatment for high risk thyroid carcinoma. The Second International
Conference on the Adjuvant Therapy of Cancer, March 1979.
22.
Salmon SE, Buick RN, Soehnlen BA, Trent JM, Durie BGM, Alberts DS, Meyskens FL:
Human tumor cloning in vitro: insights on biology kinetics and prediction of response to
treatment. The Second Annual Conference on Human Tumor Cloning, Tucson,
Arizona, January 3-5, 1980.
23.
Durie BGM, Brooks RJ: In vitro drug sensitivity testing of leukemic clonogenic cells:
Clinical correlations. Third Conference on Human Tumor Cloning, January 20-22, 1982.
24.
Salmon SE, Durie BGM: In vitro phase ΙΙ trial of 4’deoxydoxorubicin (4’deoxyDX) with
comparisons to doxorubicin (DX). American Society of Clinical Oncology (ASCO)
Annual Meeting, April 1982.
24
Royal Marsden Hospital,
25.
Bataille R, Durie BGM, Moon T, Grenier J, Sany: Interet de la Beta-2-microglobulin
serique au cours du myeloma multiple etude prospective de 160 malades. Colloque
National Sur Les Applications Cliniques de la Beta-2-Microglobuline, Nice, September
1982.
26.
Durie BGM: Experimental approaches to drug testing and clonogenic growth of multiple
myeloma and acute myelogenous leukemia. International Conference: Predictive Frug
Testing on Human Tumor Cells, University Hospital of Zurich, Switzerland, July 1983.
27.
Durie BGM: Trends and results in adult acute leukemia. Pathology Seminar Series,
March 18, 1983.
28.
Durie BGM, McFadden M: In vitro testing of a-2-interferon multiple myeloma: Single
agent and combination approaches. Seminar Schering Corp., Meadowlands, New
York, April 7, 1983.
29.
Durie BGM: Current status of HLA typing on bone marrow transplantation. Am Symp
Ariz Soc Med Tech, Tucson, Arizona, May 5, 1983.
30.
Durie BGM: Bone marrow transplantation of acute leukemia. Leukemia Society of
American Symposium, Arizona, May 6, 1983.
31.
Durie BGM: Cytogenetics and the leukemia stem cell assay.
National Society Cytogenetic Techniques, June 6, 1983.
32.
Durie BGM: Multiple myeloma: Current approaches to management. Hematology
Symposium Series, June 16, 1983.
33.
Durie BGM: New experimental approaches in multiple myeloma.
Montpellier, France, July 25, 1983.
34.
Durie BGM: Update on adult acute leukemias. Good Samaritan Hospital, Phoenix,
Arizona, August 10, 1983.
35.
Durie BGM:
Treatment for refractory multiple myeloma.
Chemotherapy Congress, Vienna, Austria, August 31, 1983.
36.
Durie BGM: Drug testing with the leukemia stem cell assay: Update of results. 13th
International Chemotherapy Congress, Vienna, Austria. September 1, 1983.
37.
Durie BGM: The pathogenesis of AIDS syndrome. Deans Rounds, Tucson, Arizona.
October 20, 1983.
38.
Durie BGM: The principles of haematopoiesis. Biology Seminar Series. October 21,
1983.
39.
Durie BGM: New concepts in multiple myeloma.
Symposium, Palermo, Italy. November 10, 1983.
25
Annual Symposium
University of
13th International
First International Myeloma
40.
Durie BGM: New approaches to myeloma colony growth. International Italian
Conference Cell Kinetics and Drug Testing in Oncology (Director:
Professor
Silverstrini), Genoa, Italy. November 11, 1983.
41.
Durie BGM: Diagnosis and treatment of hyperviscosity syndromes.
Tucson, Arizona. November 17, 1983.
42.
Durie BGM, Christiansen JA: Improved human myeloma colony growth. Blood
62:189a, 1983. American Society of Hematology, San Francisco, CA. December 5,
1983.
43.
Dalton W, Gleason M, CcCloskey T, Durie BGM, Alerts D: Reversal of drug resistance
in human multiple myeloma with verapamil (VER): design of a clinical study based on in
vitro testing using a drug resistant myeloma cell line. American Society of Clinical
Oncology (ASCO). Presented at annual meeting. May 1987.
44.
Villar HV, Ranne RD, Dunnington GL, Jones SE, Durie BGM, Grogan TM,
Wangensteen SL: The role of splenectomy in the management of hematologic
diseases. 36th Annual Southwestern Surgical Congress Meeting, Honolulu, Hawaii.
April 21-28, 1984.
45.
Durie BGM: Current approaches to the treatment of adult leukemia. Third Winder
Symposium on Hematologic Malignancies, Snowbird, Utah. February 18-25, 1984.
46.
Durie BGM: Supportive care in acute leukemia. Third Winter Symposium on
Hematologic Malignancies, Snowbird, Utah. February 18-25, 1984.
47.
Durie BGM, Pond GD, Grogan TM: Current concepts in the diagnosis and treatment of
multiple myeloma. Third Winder Symposium on Hematologic Malignancies, Snowbird,
Utah. February 18-25, 1984.
48.
Durie BGM: Southwest Oncology Group induction protocols for multiple myeloma.
Proceedings Myeloma Symposium, Padua, Italy. April 1984.
49.
Durie BGM: Multiple myeloma: Current trends and problems in staging and response
evaluation. Proceedings Myeloma Symposium, Padua, Italy. April 1984.
50.
Durie BGM: Multiple myeloma: Monocolonality versus heterogeneity.
Cambridge, England. July 17, 1974.
51.
Durie BGM: Current approaches to treatment in multiple myeloma. Ludwig Institute,
Cambridge, England. July 18, 1984.
52.
Durie BGM: Myeloma - Recent advances and future trends. University of Galway,
Ireland. September 20, 1984
26
VA Hospital,
University of
53.
Durie BGM: Current uses of interferon, lymphokines and other biologic response
modifiers as anti-cancer therapy. Alta Bates Frontiers in Oncology, Berkeley, California.
April 20, 1985.
54.
Durie BGM: Clonogenic assays: Can they be used to predict if anti-cancer agents will
work? Alta Bates Frontiers in Oncology, Berkeley, California. April 20, 1985.
55.
Durie BGM: Poly ICLC in multiple myeloma. Biological Response Modifiers Program,
National Cancer Institute, Bethesda, Maryland. April 4, 1985.
56.
Durie BGM:
The malignant cell in multiple myeloma and Waldenstrom’s
macroglobulinemia. Proc Eurage Symposium, Monoclonal Gammopathies: Clinical
Significance and basic mechanisms (Brussels, Belgium). September 19, 1985.
57.
Durie BGM: Update of therapeutic strategies in multiple myeloma. Symposium: New
Developments in B cell malignancies, Brussels, Belgium. September 21, 1985.
58.
Durie BGM: Biology of multiple myeloma. University of Toronto, Toronto, Canada.
January 27, 1986.
59.
Durie BGM: Use of alpha-interferons in combinations. Yale University, New Haven,
Connecticut. April 8, 1986.
60.
Durie BGM, Clouse L, Braich T, Grimm M, Robertone AB:
Alpha-2binterferon/cyclophosphamide combination studies: In vitro and phase Ι clinical results.
Seabrook Island Symposium. April 11, 1986.
61.
Durie BGM: Immunobiology of multiple myeloma.
Australia. May 15, 1986.
62.
Durie BGM: In vitro evaluation of the efficacy of alpha-2b-interferon. Memorial Sloan
Kettering, New York, NY. June 11, 1986.
63.
Durie BGM: The Immunology of Multiple Myeloma: XXI Congress of the International
Society of Hematology: XIX Congress of the International Society of Blood Transfusion.
1986.
64.
Durie BGM: Modulation of myeloma growth by lymphokines and accessory cells. 2nd
Sicilian International Conference on Hemato-Oncology and Hemato-Immunology. 1986.
65.
Dalton W, Gleason M, McCloskey T, Durie BGM, Alberts D: Reversal of drug
resistance in human multiple myeloma with verapamil (VER): design of a clinical study
based on in vitro testing using a drug resistant myeloma cell line. American Society of
Clinical Oncology (ASCO). Presented at annual meeting. May, 1987.
27
Proc Int Soc Hematol, Sydney,
66.
Croghan M, Durie BGM, Vela E, Dalton W: Paradoxic increased sensitivity of
chemotherapy resistant cells to the biologic agents TNF-alpha, TNF-alpha, IFN-2, plus
corticosteroids. American Association of Cancer Research (Abstract) presented at
annual meeting. May, 1987.
67.
Rossi JF, Marion SL, Pike JW, Durie BGM, Bataille B, Haussler MR, Janbon CH: 1-25
Dihydroxyvitamin D3-receptor mediated differentiation of the human myeloma cell line
RPMI 8226: phenotypic and functional analysis Workshop on cells and cytokines in
bone and cartilage, Danvos, Switzerland. December 1986.
68.
Durie BGM: Current approaches to multiple myeloma. Roswell Park Memorial Park
symposium. July 1986.
69.
Durie BGM: Myeloma:
September 25, 1986.
70.
Durie BGM: Art, science and medicine (Friday of four seminars). University of Nova
Scotia (Halifax). September 25, 1986.
71.
Durie BGM: The nature of bone disease in multiple myeloma.
Washington symposium, Seattle, Washington. October 24, 1986.
72.
Durie BGM: Role of biologic response modifiers in hematologic malignancies.
University of Tennessee, Memphis, Tennessee. January 15, 1987.
73.
Durie BGM: Role of 2b interferon alone and in combination therapy.
symposium. March 31, 1987.
74.
Durie BGM: Biology and therapy of multiple myeloma. Duke University Symposium,
Seattle meeting. April 7, 1987.
75.
Durie BGM: Review of potential role of bone marrow transplantation in multiple
myeloma, Seattle Symposium: Fred Hutchison Cancer Center. April 27, 1987.
76.
Durie BGM: Current concepts of multiple myeloma. University of Ontario, Hamilton
Meeting. May 14, 1987.
77.
Durie BGM: Role of 2b interferon and other biologic agents in multiple myeloma.
Argentine Society of Oncology Symposium (1st International), Buenos Aires, Argentina.
June 26, 1987.
78.
Durie BGM: Plasma cell neoplasms: current status. FACP Symposium, Columbus,
Ohio. September 15, 1987.
79.
Durie BGM: Plasma cell neoplasms: a review. Harvard Cancer Medicine Course,
Boston, Massachusetts. September 16, 1987.
80.
Durie BGM: Role of biologic agents in multiple myeloma. Atlantis Symposium.
biology and therapy.
28
University of Nova Scotia (Halifax).
University of
Boston
81.
West Palm Beach, Florida. September 18, 1987.
82.
Durie BGM: The biology of myeloma. Blenheim Palace Symp. October 24, 1987.
83.
Hicks MJ, Durie BGM: Prospective evaluation of immune parameters in patients with
multiple myeloma: low circulating T helper cell levels predict poor prognosis. Platform
presentation, AACR Symposium, Washington, DC. February, 1988.
84.
Karanes C, Kopecky KJ, Durie BGM, Grever M.R.: Increased risk of early death (ed)
with high dose ARA-C (HDAC) and m-AMSA compared to HDAC alone or HDAC and
Mitoxantrone (Mitox) in high risk nolymphocytic leukemia (ANL). American Society of
Clinical Oncology (ASCO). Presented at annual meeting. San Francisco, California.
March, 1989.
85.
Durie BGM: Chemotherapy of myeloma: SWOG studies.
October 26, 1987.
86.
Durie BGM: New biologic observations and the pathogenesis of multiple myeloma.
International Workshop on Multiple Myeloma. Torino, Spain. April 9-12, 1991.
87.
Durie BGM: Prognostic factors and staging in myeloma. Second International Myeloma
Workshop. Houston, Texas. July 1989.
88.
Durie BGM: Risk factors for myleoma: influence of familial genetics and environmental
exposures.
Fourth International Myeloma Workshop. Mayo Clinic, Rochester.
September 1993.
89.
Durie BGM: Beta-2 Microglobulin as a Prognostic Factor in Multiple Myeloma.
Proceedings of Multiple Myeloma, from Biology to Therapy. Current Concepts.
Mulhouse, France. October 24-26, 1994.
90.
Durie BGM: The significance of Bcl-2 and L1% in myeloma prognosis.
International Myeloma Workshop. La Baule, France. September 1995.
91.
Durie BGM, Gale RP, Klein JP, Pelz C, Nugent ML, Horowitz MM: Allogeneic Bone
Marrow Transplantation In Multiple Myeloma: An IBMTR Analysis. Proceedings of the
International Workshop on Multiple Myeloma. La Baule, France. September 10-13,
1995.
92.
Durie BGM, Gale RP, Klein JP, Pelz C, Nugent ML, Horowitz MM: Allogenic Bone
Marrow Transplantation In Multiple Myeloma: An IBMTR Analysis. American Society of
Clinical Oncology (ASCO). March, 1995.
93.
Durie BGM, Gale RP, Dubois R, Naumov IM, Anderson KC, Audeh WM, Bergsagel D,
Jagannath S, Kyle RA, Oken MM, Perlman M, Rifkin RM, Stone MJ: Multiple Myeloma:
Rand-Delphi Analysis of Appropriateness of Peripheral Blood and Bone Marrow
Autotransplants with Comparisons Using the Analytic Hierarchy Decision Process.
BLOOD. 86:10 Suppl. 1, November 15, 1995.
29
Blenheim Palace Symp.
Fifth
94.
Durie BGM, Gale RP, Dubois R, Naumov IM, Anderson KC, Audeh WM, Bergsagel D,
Jagannath S, Kyle RA, Oken MM, Perlman M, Rifkin RM, Stone MJ: Multiple Myeloma:
Rand-Delphi Analysis of Appropriateness of Peripheral Blood and Bone Marrow
Autotransplants with Comparisons Using the Analytic Hierarchy Decision Process.
American Society of Clinical Oncology. March 1996.
95.
Durie BGM, Nguyen K, Mochelson M, Waxman A: Technetium - 99m-MIBI Scanning in
Multiple Myeloma. BLOOD 88:10, Suppl. 1, page 393a. November 15, 1996.
96.
Ludwig H, Fritz E, Neuda J, Durie BGM: Which risk/benefit tradeoffs would lead
patients with myeloma to opt for interferon treatment? American Society of Clinical
Oncology. May 19, 1997.
97.
Durie BGM: Clinical utility of 99Tc MiBi imaging in myeloma.
Myeloma Workshop. Boston, Mass. October 1997.
98.
Durie BGM, Villarete L, Farvard A, Ornopia M, Umovitz HB: Circulating nucleotide
sequence in myeloma reveals presence of critical 14q32 break point region containing
SV40 T-Ag, plus Rb and P53 . Proceedings of the American Society of Hematology
annual meeting.
BLOOD. 90:10 Suppl 1. November 15, 1997.
99.
Durie BGM, Villarete L, Farvard A, Ornopia M, Urnovitz HB: Clarithromycin (Biaxin) as
primary treatment for myeloma. Proceedings of the American Society of Hematology
annual meeting. BLOOD. 90:10 Suppl 1. November 15, 1997.
Sixth International
100. Durie BGM: Expression of Du Alu RNA in the plasma of patients with active myeloma.
Seventh International Myeloma Workshop. Stockholm, Sweden. September 1999.
101. Durie BGM: Efficacy of low dose thalidomide in relapsing myeloma.
International Myeloma Workshop. Stockholm, Sweden. September 1999.
Seventh
102. Durie BGM, Martin J: Stealth Virus and active myeloma: clinical correlations. BLOOD.
94:10 Suppl 1. November 15, 1999.
103. Jacobson J, Hussein M, Barlogie B, Durie BGM, Crowley J: Beta 2 Microglobulin (B2M)
and Albumin Define a New Staging System for Multiple Myeloma: The Southwest
Oncology Group (SWOG) Experience. BLOOD. 98:11. November 16, 2001 Part 1.
104. Durie BGM, Stepan D: Low Dose Thalidomide Alone and in Combination: Long Term
Follow-Up. BLOOD. 98:11. November 16, 2001 Part 1.
105. Durie BGM, Waxman A, D’Agnolo A: Prognostic Value of Whole Body FDG/PET
Scanning In Multiple Myeloma. BLOOD. 96:11. November 16, 2002 Part 1.
106. Durie BGM, Jacobson J, Barlogie B, Crowley J: Time to First Progression Is the Best
Predictor of Survival Duration in SWOG Standard Dose Chemotherapy Studies.
American Society of Hematology (ASH). December 2002.
30
107. Durie BGM, et al. Circulating Nucleic Acids in multiple myeloma: presence of noncoding/ intergenic DNA reflects disease activity. Abstract #5095. Blood, 106 (11),
December 2005. (ASH)
108. Durie BGM, et al. Deep vein thrombosis in myeloma: estimates of problem and
recommendations for therapy based upon a survey of members of the International
Myeloma Working Group. Abstract #3571. Blood, 108(11), December 2006. (ASH)
109. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood
of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high
risk gene signatures. Abstract # 816. Blood. 110(11), November 2007 (ASH).
110. Durie B. Treatment of haematological malignancies: Durable remissions and quality of
life as primary goals. June 2008 (EHA).
PUBLICATION OF KEY ARTICLES IN MAJOR JOURNALS
Journal
Number
Blood
20
Journal of Clinical Oncology
13
British Journal of Haematology
13
Cancer
10
Cancer Research
8
Lancet
7
Leukemia
7
New England Journal of Medicine
6
Science
4
Journal of the American Medical Association
3
Nature
2
31
RESEARCH PUBLICATIONS OVERVIEW
Key publications selected from following Research Publications list.
1.
Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of
measured myeloma cell mass with presenting clinical features response to treatment
and survival. Cancer, 36: 842-854, 1975.
2.
Durie BGM, Salmon SE: High-speed scintillation autoradiography. Science 190:10931095, 1975.
3.
Jones Se, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and
cyclophosphamide for advanced breast cancer. Cancer, 36:90-97, 1975.
4.
Alberts DS, Durie BGM, Salmon SE: Doxorubicin/BCNU chemotherapy for multiple
myeloma in relapse. Lancet 1:926-928, 1976.
5.
Durie BGM, Salmon SE, Russell DH: Polyamines as makers of response and disease
activity in cancer chemotherapy. Cancer Res 37:214-221,1977.
6.
Durie BGM, Giles HR: Successful treatment of acute leukemia during pregnancy. Arch
Int Med 137:90-91, 1977.
7.
Alberts DS, Durie BGM, Salmon SE: Treatment of multiple myeloma in remission with
anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep 61:381388, 1977.
8.
Durie BGM, Mundy GR, Salmon SE: Osteoclast stimulating factor. Correlation with
measured myeloma cell mass and clinical features in patients with multiple myeloma.
Calcified Tissues Res Suppl: 319, 1978.
9.
Salmon SE, Hamburger AW, Soehnien BS, Durie BGM, Alberts DS, Moon TE:
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N
Engl J Med 298:1321-1327, 1978.
10.
Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics and
prognosis in multiple myeloma. Blood 55:364-372, 1980.
11.
Durie BGM, Russell DH, Salmon SE: The plateau phase in multiple myeloma: A
reappraisal Lancet 65-68, July, 1980.
12.
Durie BGM, Salmon SE, Mundy GR: Relation of osteoclast activating factor (OAF)
production to the extent of bone disease in multiple myeloma. Br J Haematol 47:21-30,
1981.
13.
Durie BGM, Hellman D, O’Mara RE, Woolfenden J, Kartchnet M, Salmon Se:
High-risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer
Clin Trials 4:67-73, 1981.
32
14.
Durie BGM, Cole PW, Chen H-SG, Himmelstein KJ, Salmon SE: Synthesis and
metabolism of Bence-Jones protein and calculation of tumor burden in patients with
Bence-Jones myeloma. Br J Haematol 47:7-19, 1981.
15.
Durie BGM, Salmon SE: The current status and future prospects of treatment for
multiple myeloma. In: Clinic in Haematology 11:181-210, 1982.
16.
Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production
in human myeloma stem cell culture with morphologic evidence of amyloid secretion by
associated macrophages. N Engl J Med 307:1689-1692, 1982.
17.
Durie BGM, Young LA, Simon SE: Human myeloma in vitro colony growth:
Interrelationships between drug sensitivity, cell kinetics, and patient survival duration.
Blood 61:929-934, 1983.
18.
Durie BGM: Is myeloma really a monoclonal disease? Br J Haematol 57 (3):357-363,
1984.
19.
Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini
A, Volta C, Trinalto M, Testa MG, Amadori S, Mandelli F, Durie BGM: Low
plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined
significance (MGUS) smolering myeloma and remission phase myeloma: A reliable
indicator of patients not requiring therapy. Br J Haematol 58:689-696, 1984.
20.
Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM,
Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions:
Evidence for sequential in vivo clonal change. Blood 66:548-555, 1985.
21.
Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor
survival. Blood 66:229-232, 1985.
22.
Bataille R, Durie BGM, Grenier J, Sany J: Prognostic factors and staging in
multiple myeloma: A reappraisal. J Clin Oncol, 4:80-87, 1986.
23.
Durie BGM, Dixon B, Carter S, Stephens R, Bonnet J, Morrison F, Costanzi J,
Salmon SE: Improved survival duration with combination chemotherapy induction for
multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 4:1127-1237,
1986.
24.
Garrett I, Durie BGM, Nedwin G, Gillespie A, Bringman T, Sabatini M, Bertolini
D, Mundy G: Production of lymphotoxin, a bone-resorbing cytokine, by cultured
human myeloma cells. New Engl J Med, 317:526-532, 1987.
25.
Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with
verapamil. Brit J Haemat, 68:203-206, 1988.
26.
Buzaid A, Durie BGM: Management of refractory myeloma. J Clin Onc. 6(5): (889905), 1988 .
33
27.
Durie BGM, Grogan TM, Spier C, Vela E, Baum V, Rodriquez MA, Frutiger Y:
Myelomonocytic myeloma cell line (LB84-1). Blood, Vol 73, No 3, Feb 15 1989 (p770776).
28.
Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J,
Coltman C: Prognostic value of pretreatment serum β2 microglobulin in myeloma: A
Southwest Oncology Group Study. Blood, 75:823-830, 1990.
29.
Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y,
Richter L, Grogan T: Plasma cells in multiple myeloma express a natural killer cellassociated antigen: CD56 (NKH-1;Leu-19). Blood, 76:377-382, 1990.
30.
Durie BGM: Reversal of Drug Resistance with Verapamil in Multiple myeloma. Brit J
Haemotol, 76:155-156, September 1990.
31.
Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE:
Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to
separate monoclonal gammopathy from multiple myeloma. Brit J Haematol, 83:63-67,
1993.
32.
Durie B, Urnovitz J. Cell and molecular biology of simian virus 40: Implications for
human infections and disease. J Nat Ca Instut. 91(13):1166-1167, 1999.
33.
Durie BGM, Urnovitz HB, Murphy WH: RT-PCR amplicons (RNA) in the plasma of
multiple myeloma patients, clinical relevance and molecular pathology.
Acta
Oncologica. 39 (No. 7): 789-796, 2000.
34.
Durie BGM, Stepan DE: Efficacy of low dose thalidomide in multiple myeloma. Elec J
Onc, 2000, 1, 1-8. Available at www.Elecjoncol.org/ejo/cgi-bin/Escripts2000.pl
35.
Durie BGM: Low-dose thalidomide in myeloma: efficacy and biologic significance.
Seminars in Oncology, 29 (No 6, Suppl 17): 34-38, 2002.
36.
Greipp PR, San Miguel JF, Durie BGM: Development of an international prognostic
index (IPI) for myeloma: report of the international myeloma working group. The Hem J,
Vol 4, Suppl 1: 71, 2003.
37.
Durie BGM, Waxman AD, D’Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in
multiple myeloma. J Nucl Med, 44: 632-634, 2003.
38.
Criteria for the classification of monoclonal gammopathies, multiple myeloma, and
related disorders: a report of the International Myeloma Working Group. Br J Haematol,
121: 749-757, 2003.
39.
Durie BGM, Waxman AD, D’Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in
multiple myeloma. J Nucl Med, 44: 632-634, 2003.
34
40.
Durie BGM, Jacobson J, Barlogie B, et al. Time to progression, but not magnitude of
regression predicts survival benefit in SWOG standard dose chemotherapy studies for
multiple myeloma. J. Clin Onc, 22: 1857-1963, 2004.
41.
Durie BGM. New Approaches to Treatment for Multiple Myeloma: Durable Remission
and Quality of Life as Primary Goals. Clin Lymphoma Myeloma, 6 (3): 181-90, 2005.
42.
Durie BGM, Katz M, McCoy J, et al: Osteonecrosis of the jaw and bisphosphonates.
New Eng. J. Med, Jul 7, 353(1): 99-102, 2005.
43.
Durie BGM, Harousseau JL, et al. International uniform response criteria for multiple
myeloma. Leukemia, 20:1467-1473, 2006.
44.
Durie BG, Attal M, Beksac M, et al. Use of bisphosphonates in multiple myeloma: IMWG
response to Mayo Clinic consensus statement. Mayo Clin Pro, 82:516-522, 2007.
45.
Durie BGM. (Editorial) Treatment of myeloma- Are we making progress?. New Engl J
Med, In Press, August 2008.
46.
Durie BGM. (Commentary) Crossover confusion: MPT still best. Blood, In Press,
September 2008.
47.
Durie BGM.(Commentary- 25th Year Anniversary Issue) Myeloma therapy: 25 years
forward- Immune modulation then and now. J Clin Oncol, In Press, October 2008.
RESEARCH PUBLICATIONS
JOURNALS
1.
Durie BGM, Stroud JD, Kahn JA: Progressive systematic sclerosis with malignant
atrophic papulosis. Arch Dermatol 100:575, 1969.
2.
Durie BGM: Computers: Historical review; applications in medicine and hematology
Hematol Sem, 6:543-553, 1970.
3.
Durie BGM, Peters GA:
28:569, 1970.
4.
Gill W, Carter DC, Durie BGM: Retroperitoneal tumors: A review of 134 cases. J Royal
Coll Surg (Edinburgh), 15:213-221, 1973.
5.
Durie BGM, Taswell HG: HL-A antigens in myelomonocytic leukemia; results in 95
patients. Transplantation, 6:397-399, 1973.
6.
Sieber O, Fulginiti V, Durie BGM, Salmon S: Successful immunological reconstruction
in severe combined immunodeficiency disease with transplantation from a noncompatible donor. Clin Res 14:193, 1973.
Cardiac arrhythmia following a hornet sting. Ann Allergy,
35
7.
Durie BGM, Taswell HF: Lymphocyte responses in the Sezary Syndrome (T-cell
erythroderma). Archives of Dermatol, 108:205, 1973.
8.
Jones SE, Salmon SE, Durie BGM: Failure of indium 111-labeled bleomycin tumor
scanning to predict response to bleomycin (NSC-125066) treatment. Cancer Chemother
Rep 58 (part 1):733-735, 1974.
9.
Durie BGM, Taswell HF: Cell-mediated immunity in patients with myelomonocytic
leukemia. J Immunol Meth, 16:331-339, 1974.
10.
Salmon SE, Durie BGM: Le myeloma et la macroglulinemie Idiopathique. Cashiers
Integres de Medecine. Hematologie, cancerologie et Immunologie applique. V.
No. 105, March 9,
Cancerologie (5), Hemopathies Malignes. Masson et Ce, Paris.
1974.
11.
Durie BGM, Salmon SE: Evaluation and treatment of multiple myeloma and related
disorders. (J. Vaeth, ED.), S. Karger AG, Medical and Scientific Publishers, Basel,
Switzerland, Front Radiat Ther Oncol, 10:170-177, 1974.
12.
Durie BGM: Therapy of acute leukemia. AZ Med, 31:283-284, 1974.
13.
Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of
measured myeloma cell mass with presenting clinical features response to treatment
and survival. Cancer, 36: 842-854, 1975.
14.
Durie BGM, Salmon SE: High-speed scintillation autoradiography. Science 190:10931095, 1975.
15.
Salmon SE, Durie BGM: Cellular kinetics in multiple myeloma: A new approach to
staging and treatment. Arch Int Med, 135:131-138, 1975.
16.
Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. A new
approach to staging and treatment. Arch Int Med, 135:131-138, 1975.
17.
Jones Se, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and
cyclophosphamide for advanced breast cancer. Cancer, 36:90-97, 1975.
18.
Durie BGM, Salmon SE: Cellular kinetics, staging and immunoglobulin synthesis in
multiple myeloma. Ann Review Med, 26:283-288, 1975.
19.
Russell DH, Durie BGM, Salmon SE: Polyamines as predictors of success and failure
in cancer chemotherapy. Lancet 2:797-799, 1975.
20.
Jones SE, Lilien DL, O’Mara RE, Durie BGM, Salmon SE: Indium-111 bleomycin tumor
scanning in lymphoma. Med Ped Oncol 1:11-21, 1975.
36
21.
Jones SE, Lilien DL, O’Mara RE, Salmon SE, Durie BGM: A clinical evaluation of
indium-111 bleomycin as a tumor-imaging agent. Cancer 35:1036-1049, 1975.
22.
McMahon LJ, Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with
methyl-CCNU (NSC-95441), cyclophophamide (NSC-26271), vincristine (NSC-67574),
methotrexate (NSC-740), and bleomycin (NSC-125066), in advanced bronchogenic
carcinoma. Cancer Letters 1:97-102, 1975.
23.
Kleckner HB, Durie BGM, Schnur PL: Current trends in malignant melanoma. AZ
Med, 33:468-470, 1976.
24.
Salmon SE, Durie BGM: Application of kinetics to chemotherapy for multiple
myeloma. Proceedings 29th annual symposium on Fundamental Cancer Research,
(Williams and Wilkins) 865-878, 1976.
25.
Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon LJ: Combination
chemotherapy with adriamycin (NSC-123127), and cyclophosphamide (NSC-26271), for
solid tumors: A phase II trial. Cancer Treat Rep 60:77-83, 1976.
26.
Alberts DS, Durie BGM, Salmon SE: Doxorubicin/BCNU chemotherapy for multiple
myeloma in relapse. Lancet 1:926-928, 1976.
27.
Durie BGM, Salmon SE: Multiple myeloma, macroglobulinemia and monoclonal
gammopathies. In: Recent Advances in Haematology. (AV Hoffbrand, MC Brain, J
Hirsch, Eds). Churchill Livingston, London, Edinburgh. Chapter 13:243-261, 1977.
28.
Durie BGM, Hellman D, O’Mara RE, Woolfenden J, Kartchner M, Salmon SE:
Multimodality treatment for high risk thyroid carcinoma. In: Adjuvant Therapy of Cancer
(SE Salmon, SE Jones, Eds.) Elsevier/North Holland Press, Amsterdam. Pages 475486, 1977.
29.
Durie BGM, Salmon SE, Russell DH: Polyamines as makers of response and disease
activity in cancer chemotherapy. Cancer Res 37:214-221,1977.
30.
Durie BGM, Giles HR: Successful treatment of acute leukemia during pregnancy. Arch
Int Med 137:90-91, 1977.
31.
Alberts DS, Durie BGM, Salmon SE: Treatment of multiple myeloma in remission with
anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep 61:381388, 1977.
32.
Durie BGM: Scintillator distribution in high-speed autoradiography. Science 195:208,
1977.
37
33.
Jones SE, Tucker WG, Haut A, Tranum BL, Vaughn C, Chase EM, Durie BGM:
Phase II trial of Piperazinedione in Hodgkin’s disease, non-Hodgkin’s lymphoma and
multiple myeloma: A Southwest Oncology Group Study. Cancer Treat Rep 61:16171621, 1977.
34.
Salmon SE, Durie BGM: Clinical staging and new therapeutic approaches in multiple
myeloma. Recent Results in Cancer Res.,65:12-20, 1978.
35.
Durie BGM, Mundy GR, Salmon SE: Osteoclast stimulating factor. Correlation with
measured myeloma cell mass and clinical features in patients with multiple myeloma.
Calcified Tissues Res Suppl: 319, 1978.
36.
Cole PW, Durie BGM, Salmon SE: Immunoquantitation of free light chain
immunoglobulins. Applications of multiple myeloma. J Immunol Meth 19:341-349, 1978.
37.
Durie BGM, Vaught L, Chen YP, Olson GB, Salmon SE, Bartels PH: Discrimination
between T and B lymphocytes and monocytes by computer analysis of digitized data
from scanning microphotometry: I. Chromatin distribution patterns. Blood 51:579-589,
1978.
38.
Rosenblum MG, Durie BGM, Salmon SE, Russell DH: Metabolism of
[14C]Spermidine [14C] Putrescine in normal volunteers and in cancer patients. Cancer
Res 38:3161-3163, 1978.
39.
Salmon SE, Hamburger AW, Soehnien BS, Durie BGM, Alberts DS, Moon TE:
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N
Engl J Med 298:1321-1327, 1978.
40.
Rosenblum MG, Durie BGM, Beckerman RC, Taussig LM, Russell DH: Cystic
fibrosis: Decreased conjugation and excretion of [14C] spermidine. Science 200: 14961497, 1978.
41.
Russell DH, Rosenblum MG, Beckerman RC, Durie BGM, Taussig LM, Barnett
DR: Altered polyamine metabolism in cystic fibrosis. Ped Res 13:1137-1140, 1979.
42.
Salmon SE, Alberts DS, Durie BGM, Meyskens FL, Soehnlen BA, Chen H-SG,
Moon TE: Clinical correlation of drug sensitivity in the human tumor stem cell assay.
Recent Results in Cancer Research Proc. of EORTC Plenary Session on Cancer and
Chemo-Immunopharmacology Paris, June 20-22, 1979. Recent results in Cancer Res
74:300-305, 1980.
43.
Hellman DE, Durie BGM, Woolfenden JM, Kartchner M: Multi-disciplinary
management of carcinoma of the thyroid. AZ Med, 37:19-25, 1980.
44.
Levine AS, Durie BGM, Lampkin B, Leventhal BG, Levy HB: Poly (ICLC):
Interferon induction, toxicity and clinical efficacy in leukemia, lymphoma, sold tumors,
myeloma and laryngeal papillomatosis. Proc 2nd International Conf Immunotherapy of
Cancer NCI, NIH, 1980.
38
45.
Durie BGM: The role of polyamines as predictors of success and failure in cancer
chemotherapy. (Vol 2:113-122). In: Tumor Progression (Ray G Crispen Ed),
Developments in Cancer Research, Elsevier North Holland, Inc., publishers, 1980.
46.
Durie BGM: Lambda myelomas. Proceedings of Workshop on Recent Advances and
Future Trends in Myeloma. Institut National de la Sante et de La Recherche Medicale,
Montpellier, France. Elsevier/North Holland Biomedical Press, 1980.
47.
Durie BGM: Labeling indices and prognosis of myeloma. Proceedings of Workshop on
Recent Advances and Future Trends in Myeloma. Institut National de la Sante et de la
Recherche Medicale, Montpellier, France. Elsevier/North Holland Biomedical Press,
1980.
48.
Durie BGM, Salmon SE: Use of Clodronate in the treatment of hypercalcemia in
multiple myeloma. Proceedings of Workshop on Recent Advances and Future Trends in
Myeloma. Institut National de la Sante et de La Recherche Medicale, Montpellier,
France. Elsevier/North Holland Biomedical Press, 1980.
49.
Jones SE, Salmon SE, Alberts DS, Meyskens FL, Durie BGM, Chen H-SG: In
vitro phase II trial of vinca alkaloids. Proceedings of the International Vinca Alkaloid
Symposium-Vindesine, Frankfurt Am, November 1980.
50.
Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics and
prognosis in multiple myeloma. Blood 55:364-372, 1980.
51.
Durie BGM, Russell DH, Salmon SE: The plateau phase in multiple myeloma: A
reappraisal Lancet 65-68, July, 1980.
52.
Bataille R, Durie BGM, Salmon SE: Myeloma bone marrow acid phosphatase
staining: A correlative study of 38 patients. Blood 55:802-805, 1980.
53.
Woolfenden JM, Platt MJ, Durie BGM, Moon TE: Comparison of bone scintigraphy
and radiography in multiple myeloma. Radiology 134:723-728, 1980.
54.
Durie BGM, Salmon SE: Therapeutic strategie in multiple myeloma. Bull Cancer
(Paris) 64 (4) :450-457, 1980.
55.
Durie BGM: Bone marrow transplantation for acute nonlymphoblastic leukemia. N
Engl J Med, 302:408, 1980.
56.
Garewal H, Durie BGM: Beta2-Microglobulin: A potentially useful marker for
hematologic malignancies. AZ Med, 38:912-913, 1981.
57.
Salmon SE, Alberts DS, Meyskens FL, Durie BGM, Jones SE, Moon TE: Tumor
cells and adjuvant chemotherapy: Perspectives in 1981. In: Adjuvant Therapy of Cancer
III, Grune & Stratton, 13-23, 1981.
39
58.
Durie BGM: Cloning efficiency and monitoring of the chemotherapy of plasma cell
myeloma. Ettore Majorana, Centre for Scientific Culture. International School of Medical
Sciences. Advances in Lymphoproliferative Disorders, 15th Course: 309:319, 1981.
59.
Durie BGM, Salmon SE, Mundy GR: Relation of osteoclast activating factor (OAF)
production to the extent of bone disease in multiple myeloma. Br J Haematol 47:21-30,
1981.
60.
Durie BGM, Hellman D, O’Mara RE, Woolfenden J, Kartchnet M, Salmon Se:
High-risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer
Clin Trials 4:67-73, 1981.
61.
Durie BGM, Cole PW, Chen H-SG, Himmelstein KJ, Salmon SE: Synthesis and
metabolism of Bence-Jones protein and calculation of tumor burden in patients with
Bence-Jones myeloma. Br J Haematol 47:7-19, 1981.
62.
Dana B, Durie BGM, White RF, Huestis DW: Concomitant administration of
granulocyte transfusions and amphotericin B in neutropenic patients: Absence of
significant pulmonary toxicity. Blood 57:90-94, 1981.
63.
Hofmann V, Salmon SE, Durie BGM: Drug resistance in multiple myeloma
associated with high in vitro incorporation of 3[H]-Thymidine. Blood 58 (3):471-476,
1981.
64.
Durie BGM, Valeriote, Phillips, Schiffer: Cancer research impact of the cooperative
groups. Basic Res, Masson Publishing, Chapter 20, 361-365, 1981.
65.
Moon TE, Salmon SE, White CS, Chen H-SG, Meyskens FL, Durie BGM, Alberts
DS: Quantitative association between the in vitro human tumor stem cell assay and
clinical response to cancer chemotherapy. Cancer Chemother Pharmacol 6:211-218,
1981.
66.
Durie BGM: Staging and kinetics of multiple myeloma. In: Clinics in Haematology 11:
181-210, 1982.
67.
Durie BGM, Salmon SE: The current status and future prospects of treatment for
multiple myeloma. In: Clinic in Haematology 11:181-210, 1982.
68.
Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production
in human myeloma stem cell culture with morphologic evidence of amyloid secretion by
associated macrophages. N Engl J Med 307:1689-1692, 1982.
69.
Garewal H, Durie BGM: Aggressive phase of multiple myeloma with pulmonary
plasma cell infiltrates. JAMA 348:1875-1876, 1982.
40
70.
Brooks RJ, Dorr RT, Durie BGM: Interaction of allopurinol with 6- mercaptopurine
and azathioprine: Case report and review of the literature. Biomedicine 36:217-222,
1982.
71.
Herman TS, Durie BGM, Hutter JJ: Treatment of patients with refractory
myelogenous leukemia with BCOMM (1, 3-bis-chloro (2-chloroethy1)-1-nitrosourea
(BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotraxate and methylglyoxal bisquanylhydrazone (MGBG) ]. Cancer Chemother Pharmacol 8:73-75, 1982.
72.
Ahmann FR, Meyskens FL, Moon TE, Durie BGM, Salmon SE: In vitro
chemosensitivities of human tumor stem cells to phase II drug (M. AMSA) 4’ - (9acridinylamino) methanesulfon-m-anisidide and prospective in vivo correlations.
Cancer Res 42: 4495-4498.
73.
Durie BGM, Young LA, Simon SE: Human myeloma in vitro colony growth:
Interrelationships between drug sensitivity, cell kinetics, and patient survival duration.
Blood 61:929-934, 1983.
74.
Trent JM, Durie BGM, Davis JR, Veomett I: Cytogenetic and clinical assessment of
six patients with erythroleukemia. Anticancer Res 3:111-116, 1983.
75.
Dana BW, Durie BGM, White RF, Huestis DW, Paplanus S: The significance of
pulmonary infiltrates developing in patients receiving granulocyte transfusions. Br J
Haematol 53 (3):437- 443, 1983.
76.
Trent JM, Davis JR, Durie BGM: Cytogenetic analysis of leukemia colonies from
acute and chronic myelogenous leukemia. Br J Cancer 47:103-109, 1983.
77.
Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N: Effects of
cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol
1:217-225, 1983
78.
Ludwig CU, Durie BGM, Salmon SE, Moon TE: Tumor growth stimulation in vitro
by interferons. Eur J Cancer Clin Oncol 19:1625-1632, 1983.
79.
Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM, Dixon DO:
Alternating combination chemotherapy and levamisole improve survival in multiple
myeloma. A Southwest Oncology Group Study. J Clin Oncol 1:453:461, 1983.
80.
Boccadoro M, Gavarotti P, Fossati G, Massaia M, Pileri A, Durie BGM: Kinetics
of circulating B Lymphocytes in human myeloma. Blood 61:812-814, 1983.
81.
Bataille R, Durie BGM, Grenier J: Serum beta-2-microglobulin and survival duration
in multiple myeloma: A simple reliable marker for staging. Br J Haematol 55:439-447,
1983.
82.
Wirt DP, Grogan TM, Payne CM, Kummet TD, Durie BGM, et al: Phagocytic,
lambda light chain, plasma cell myeloma. Am J Clin Path 80:75-84, 1983.
41
83.
Ludwig CH, Hicks MNJ, Pena D, Durie BGM: OKT-8+-suppressor-T-lymphozyten
sind bei patienten mit stabilem multiple myelona vermehrt. Schweiz med Wschr
113:1451-1454, 1983.
84.
Ahmann FR and Durie BGM: Acute myelogenous leukemia modulated by B12
deficiency: A case with bone marrow blast cell assay corroboration. Br J Haematol
58:91-94, 1984.
85.
Durie BGM: New approaches to myeloma colony growth. Proc Int Conf Cell Kinetics
and Drug Testing in Oncology (Santa Margh., Italy), 1984.
86.
Berdeaux D, Durie BGM: Idiopathic thrombocytopenia purpura (ITP)in pregnancy. Az
Med XLI (2) : 240-243, 1984.
87.
Durie BGM: The plasma cell diseases. Proceedings of the Eighth Annual Cancer
Symposium (San Diego, CA ), October, pp. 234-245, 1984.
88.
Durie BGM: Multiple myeloma. Current trends and problems in staging and response
evaluation. Proceedings Myeloma Symposium, Padua, Italy, April, 1984.
89.
Durie BGM: Southwest Oncology group induction protocols for multiple myeloma.
Proceedings Myeloma Symposium, Padua, Italy, April, 1984.
90.
Durie BGM: Recent advances in multiple myeloma and related monoclonal
gammopathies. Current Haematol 3:239-286, 1984.
91.
Hutter JJ, Hecht F, Kaiser-McCaw B, Hays T, Baranko P. Cohen J, Durie BGM:
Bone marrow monosomy 7: Hematologic and clinical manifestations in childhood and
adolescence. Hematol Oncol 2:5-12, 1984.
92.
Garewal H, Durie BGM, Kyle RA, Finley P, Bower B, Serokman R: Serum beta-2
microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell
disorders. J Clin Oncol 2:51-57, 1984.
93.
Durie BGM: Is myeloma really a monoclonal disease? Br J Haematol 57 (3):357-363,
1984.
94.
Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini
A, Volta C, Trinalto M, Testa MG, Amadori S, Mandelli F, Durie BGM: Low
plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined
significance (MGUS) smolering myeloma and remission phase myeloma: A reliable
indicator of patients not requiring therapy. Br J Haematol 58:689-696, 1984.
95.
Durie BGM: Experimental approaches to drug testing and clonogenic growth: Results
in multiple myeloma and acute myelogenous leukemia. Proc Int Conf Predictive Drug
Testing on Humans Tumors Cells (Zurich) Recent Results in Cancer Res 94:93-101,
1984.
42
96.
Ahmann FR, Jones SE, Moon TE, Hammond N, Miller TP, Durie BGM: Chemohormonal therapy for advanced breast cancer with Tamoxifen, adriamycin, and
cyclophosphamide (TAC). Cancer 56:730 - 737, 1985.
97.
Durie BGM: Current thinking about the management of multiple myeloma and related
disorders. Oncology Mediguide, 5 (2) : 1-5, 1985.
98.
Durie BGM: The malignant cell in multiple myeloma and Waldenstroms
macroglobulinemia. Proc Europe Symp. Monoclonal Gammapathies: Clinical
significance and basic mechanism (Brussels, Belgium), September 1: 25-34, 1985.
99.
Dalton WS, Durie BGM: Cell cycle kinetics and applications to cancer chemotherapy.
Hospital Therapy, 12:43-49, 1985.
100. Crossen PE, Broderick RD, Durie BGM, Trent JM: Proliferative characteristics and
sister chromatid exchange (SCE) of colony-forming cells (CFU-S) in acute myelogenous
leukemia. Cancer Genet Cytogenet 14:267-273, 1985.
101. Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM,
Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions:
Evidence for sequential in vivo clonal change. Blood 66:548-555, 1985.
102. Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor
survival. Blood 66:229-232, 1985.
103. Greenberg BR, Durie BGM, Co Barnett T, Meyskens FL Jr: Phase I-II study of 13cis-retinoic acid (isotretinoin) in myelodysplastic disorders. Cancer Treat Rep 12:13691374, 1985.
104. Durie BGM, Soehnlen BJ, Prudden JF: Antitumor activity of bovine cartilage extract
(CATRIX-S) in the human tumor stem cell assay. J Biol Resp Mod 4:590-595, 1985.
105. Ahmann FR, Jones SE, Moot Te, Hammond N, Miller TP, Durie BGM: Chemohormonal therapy advanced breast cancer with Tamoxifen, adriamycin, and
cyclophosphamide (TAC). Cancer 56:730-737, 1985.
106. Garewel HS, Corrigan JJ, Durie BGM, Jeter MA, Damiano ML: Effect of Danazol
on coagulation parameters and bleeding in hemophilia. JAMA 253 (8):1154-1156,
1985.
107. Greenberg BR, Grogan TM, Takasugi BJ, Trent JM, Hicks MJ, Durie BGM: A
unique malignant T-cell lymphproliferative disorder with neutropenia stimulating hairy
cell leukemia. Cancer 56:2823-2830, 1985.
108. Kronland R, Grogan T, Spier C, Wirt D, Rangel C, Richter L, Durie BGM,
Greenberg B, Miller T, Jones S: Immunotopographic assessment of lymphoid and
plasma cell malignancies in the bone marrow. Hum Pathol 16:1247-1254, 1985.
43
109. Durie BGM: The role of interferons in multiple myeloma. Interferon Letter II (3):5,
1985.
110. Durie BGM: Studies with interferons in the human tumor assay system. Interferon
Letter II (3):1, 1985.
111. Garewal HS, Durie BGM: Anti-fibrinolytic therapy with aminocaproic acid for control of
bleeding in thrombocytopenia patients. Scan J Haematol, 35:497-500, 1985.
112. Durie BGM, Levy HB, Voakes J, Jett JR, Levine AS: Poly (I,C)-LC as an
interferon inducer in refractory multiple myeloma. J Biol Resp Mod 4:518-524, 1985.
113. Garewal Hs, Corrigan JJ, Jeter MA, Damiano ML, Durie BGM: Danazol induced
factor VIII and IX bypassing activity in hemophiliacs.
114. Durie BGM, Clouse L, Braich T, Grimm M, Robertone AB: Alpha-2binterferon/cyclophosphamide combination studies: In vitro and phase I clinical results.
Sem Oncol 3 Suppl: 84-88, 1986.
115. Pond GD, Dean JC, Durie BGM, Brumbaugh P: Experience with intra-arterial
adriamycin as part of combination therapy for extremity sarcoma. Cancer Chemother
Rep, 11:162-169, 1986.
116. Cole PW, Durie BGM, Meezan E, Brendal K, Salmon SE: Inhibition of pPaminohipurate transport in isolated rabbit renal tubules by free light chain
immunoglobulins from patients with Fanconi syndrome and multiple myeloma. Nephron
6:29-36, 1986.
117. Crossen PE, Durie BGM, Trent JM: Generation time (GT) of human bone marrow
cells cultured in the CFC-GM assay. Cell Tissue Kinetics,19:533-538, 1986.
118. Berdeaux DH, Glasser L, Serokamnn R, Moon T, Durie BGM: Hypoplastic acute
leukemia: Review of 70 cases with multivariate regression analysis. J Hematol Oncol,
4:291-305, 1986.
119. Bataille R, Durie BGM, Grenier J, Sany J: Prognostic factors and staging in
multiple myeloma: A reappraisal. J Clin Oncol, 4:80-87, 1986.
120. Durie BGM, Dixon B, Carter S, Stephens R, Bonnet J, Morrison F, Costanzi J,
Salmon SE: Improved survival duration with combination chemotherapy induction for
multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 4:1127-1237,
1986.
121. Fielder K, Durie BGM: Primary amyloidosis associated with multiple myeloma:
Predictors of successful therapy. AM J Med 80:413-418, 1986.
44
122. Dalton WS, Durie BGM, Alberts DS, Gerlack JH, Cress AE, Ling V:
Characterization of a new drug resistant human myeloma cell line which expresses Pglycoprotein. Cancer Research, 46:4125-5130, 1986.
123. Durie BGM: Staging and kinetics of multiple myeloma. Sem Oncol 13:300-309, 1986.
124. Kingsley EC, Durie BGM: Prolonged survival in patients with treatment related
leukemia. Scan J Haematol 37:103-105, 1986.
125. Durie BGM, Kyle R, Barlogie B: Supportive care management, induction treatment
and salvage therapy for multiple myeloma. Blood suppl. (p19-24) Dec. 1986.
126. Lippman SM, Durie BGM, Garewal HS, Giordano G, Greenberg BR: Efficacy of
danazol in pure red cell aplasia. Am J Haematol 23: 373-379, 1986.
127. Witte RS, Koeller J, Davis TE, Benson AB, Durie BGM, Lipton A, Stock JL,
Citrin DL, Canfield RE: Clodronate: A randomized placebo-controlled double-blind
study in the treatment of malignancy associated hypercalcemia. Arch Int Med 147:937939, 1987.
128. Durie BGM: Plasma cell neoplasms: current status. FACP Symposium Proceedings.
Sept. 1987 (p 94-99).
129. Durie BGM: Plasma cell neoplasms; a review. Cancer Medicine. (Harvard, Boston)
Sept. 1987 (p 94-99).
130. Durie BGM, Vela EE, Payne CM: Direct secretion of amyloid by myeloma cells. Proc Int
Amyloid Symp., 44-46, 1987.
131. Lippman SM, Grogan TM, Spier CM, Koopmann CF, Gall EP, Shimm D, Durie
BGM: Lethal midline qranuloma with a novel T-cell phenotype as found in peripheral Tcell lymphoma. Cancer 59:936-939, 1987.
132. Grogan TM, Durie BGM, Lomen C, Spier C, Nagle R, Wilson G, Richter L, Vela
E, Maxey V, McDaniels K, Rangel C: Delineation of a novel pre-B cell component in
plasma cell myeloma: Immunochemical, immunophenotypic, cytologic, cell culture and
kinetic features. Blood 70:932-942, 1987
133. Villar H, Warneke J, Peck M, Durie BGM, Bjelland J, Hunter T: Gastrointestinal
complications in leukemic patients. Surgery, Gynecology & Obstetrics, 165:217-222,
1987.
134. Durie, BGM: Immunofluorescence method improves clinical utility of myeloma cell
labeling indices. Mayo Clinic Proceedings, 62:1027-1058, 1987.
135. Garrett I, Durie BGM, Nedwin G, Gillespie A, Bringman T, Sabatini M, Bertolini
D, Mundy G: Production of lymphotoxin, a bone-resorbing cytokine, by cultured
human myeloma cells. New Engl J Med, 317:526-532, 1987.
45
136. Villar H, Warneke J, Peck M, Durie BGM, Bjelland J, Hunter T: Role of surgical
treatment in the management of complications of the gastrointestinal tract in patients
with leukemia. Surgery, Gynecology & Obstetrics, Vol. 165:217-222. September,
1987.
137. Buzaid AC, Garewal SH, Lippman SH, Durie BGM, et al: Danazol in the treatment
of myelodysplastic syndromes. Eur J Haematol 39:346-347, 1987.
138. Boccadoro M, Durie BGM, Frutiger Y, Gavarotti P, Redoglia V, Massaia M,
D’Alberto M, Marmont F, Gallamini A, Tribalto M, Pileri A: Lack of correlation
between plasma cell thymidine labeling index and serum Beta-2-microglobulin in
monoclonal gammopathies. Acta Haemat, 78:239-242, 1987.
139. Kummet TD, Durie BGM: IgM monoclonal gammopathies: A review of the Arizona
experience, with emphasis on Waldenstrom’s macroglobinemia. W. Med J 145:299306, 1987.
140. Durie BGM, Christiansen JA: Critical determinants of human myeloma colony growth:
The major role la antigen positive macrophages. Stem Cells, 4:187, 1987.
141. Ludwig R, Ludwig CU, Owens B, Christiansen JA, Durie BGM: Improved
cytochemical and immunofluorescent evaluation of human tumor colonies grown in soft
agar. Stem Cells, 4:324, 1987.
142. Villar HV, Ranne RD, Dunnington GL, Jones, SE, Durie BGM, Miller TP, Grogan
TM, Wangensteen SL: The role of splenectomy in the management of hematologic
diseases. Am J Surgery, 73:43-48, 1988.
143. Durie BGM, Payne C: Unusual membrane abnormalities in a family with congenital
dyserythropoetic anemia (CDA). Blood, 66:100, 1985.
144. Rossi JF, Durie BGM, Marion SL, Pike JW, Bataille R, Haussler M, Janbon C:
1,25 - Dihydroxyvitamin D3 - Receptor mediated differentiation of the human myeloma
cell line RPMI 8226: Phenotypic and functional analysis. Cancer Research, 48:12131216, 1988.
145. Garewal H, Durie BGM: High dose-cytosine arabinoside, daunomycin and 6thioguanine for relapsed acute non-lymphocytic leukemia. Clinic Res, 32:34, 1984.
146. Kingsley EC, Durie BGM, Garewal HS: Acute promyelocytic leukemia. Western J
Med, 146:322-327, 1988.
147. Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with
verapamil. Brit J Haemat, 68:203-206, 1988.
148. Danel V, Bataille R, Roussett F, Durie BGM, Revillard J: Expression of estrogen
and progesterone receptors by some human and murine myelomatous cell lines. J
Biochem, 34:111-119, 1988.
46
149. Buzaid A, Durie BGM: Management of refractory myeloma. J Clin Onc, Vol 6, No.
5, May 1988 (889-905).
150. Durie BGM: The biology of multiple myeloma. Proceeding Blenheim Palace myeloma
workshop. Oxfordshire, U.K., 24-26 October, 1987. Hematological Oncology, Vol 6, No
2, (p 77-83) April-June 1988.
151. Durie BGM: Chemotherapy of myeloma: SWOG studies. ProceedingsBlenheim
Palace myeloma workshop, Oxfordshire, U.K., 24-26 October,1987 Hematological
Oncology, Vol 6, No 2, (p 141-145) April-June 1988.
152. Grogan Tm, Durie BGM, Spier CM, Richter L, Vela E: Myelomonocytic antigen
positive multiple myeloma. Blood, 73:3:763-769 Feb 15, 1989.
153. Dupperay C, Klein B, Durie BGM, Zhang X, Jourdan M, Poncelet P, Favier F,
Vincent C, Brochier J, Lenoir G, Bataille R: Phenotypic analysis of human
myeloma cell lines. Blood, 73:566-572, 1988.
154. Bataille R, Durie BGM, Klein B: Antibody specificity of the human monoclonal
immunoglobulins: The elusive target antigen. Autoimmunity, 4:181-189, 1989.
155. Durie BGM, Vela E, Frutiger Y, Grogan T: Cross correlation between 3[H] thymidine,
BU-1 and Ki-67 assessment of S-phase in multiple myeloma. Proc. 13th Int. Symp.
Padua: 43, 1989.
156. Durie BGM: Development of high titre antibodies with roferon (2a) interferon in hairy cell
leukemia: subsequent response to natural leukocyte interferon. Int. Letters: 8:4, 1989.
157. Durie BGM, Haum VE, Vela E, Mundy GR: Abnormalities of chromosome 6q and TNF
(lymphotoxin or OAF) production in multiple myeloma. Proc. Cytog. Symp., 4:11, 1989.
158. Durie BGM: Classification of low grade versus high grade myeloma. Proc. 13th Scripps
Cancer Symp. 43-46, 1989.
159. Durie BGM, Grogan TM, Spier C, Vela E, Baum V, Rodriquez MA, Frutiger Y:
Myelomonocytic myeloma cell line (LB84-1). Blood, Vol 73, No 3, Feb 15 1989 (p770776).
160. Dalton WS, Grogan TP, Meltzer OS, Scheper RJ, Durie BGM, Taylor CW, Miller
TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma:
detection of P-glycoprotein and potential circumvention by addition of verapamil to
chemotherapy. J Clin Oncol, 7:415-424, 1989.
161. Hicks MJ, Durie BGM, Slymen DJ: Low circulating T-Helper Cells in Relapsing
Multiple Myeloma. J Clin Lab Anal, 3:202-208, 1989.
162. Hoyt RH, Durie BGM: Pseudothrombocytopenia induced by a Monoclonal IgM kappa
platelet agglutinin. Amer J Haem, 31:50-52, 1989.
47
163. Bataille R, Durie BGM, Klein B: Antibody specificity of the human monoclonal
immunoglobulins: the elusive target antigen. Autoimmunity, 4:181-189, 1989.
164. Bataille R, Klein B, Jourdan M, Rossi JF, Durie BGM: Spontaneous secretion of
tumor necrosis factors-beta by human myeloma cell lines. Cancer, 63:877, 1989.
165. Durie BGM, Bataille R: Therapeutic implications of myeloma staging. Eur J
Haematol, 51:111-116, 1989.
166. Rossi JF, Durie BGM, Duperray C, Braich T, Samuel L, Marion J, Pike W,
Haussler M, Janbon C, Bataille R: Phenoteypic and functional analysis of 1,25Dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line
RPMI 8226. Cancer Research, 48:1213-1216, 1989.
167. Bataille R, Klein B, Jourdan M, Ross JF, and Durie BGM: Spontaneous secretion of
tumor necrosis factor-β by human myeloma cell lines. Cancer 877-880. 1989
168. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J,
Coltman C: Prognostic value of pretreatment serum β2 microglobulin in myeloma: A
Southwest Oncology Group Study. Blood, 75:823-830, 1990.
169. Durie BGM: Interferons in the treatment of myeloma. J Clin Oncol, 2:14, 1990.
170. Spier CM, Grogan A, Durie BGM, Richter LC, Vela E, Frutiger Y, Rangel CS: TCell antigen-positive multiple myeloma. Modern Pathology, 3:302-307, 1990.
171. Durie BGM, Dodd-Tayor S: Remarkable efficacy of every other day oral prednisone in
drug refractory myeloma. Clinic Res., 36:148, 1990.
172. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y,
Richter L, Grogan T: Plasma cells in multiple myeloma express a natural killer cellassociated antigen: CD56 (NKH-1;Leu-19). Blood, 76:377-382, 1990.
173. Durie BGM: Reversal of Drug Resistancewith Verapamil in Multiple myeloma. Brit J
Haemotol, 76:155-156, September 1990.
174. Durie BGM, Vela EE, Frutiger Y: Macrophages as an Important Source of Paracrine
IL-6 in Myeloma Bone Marrow. Current Topics in Microbiology & Immunology, 166:3336, 1990
175. Durie BGM: Serum Beta-2 microglobulin (B2M) in myeloma (MM): towards a simple
prognostic stratification using B2M and acute phase proteins? Blood, 77:1616-1617,
1991.
176. Durie BGM: New biologic observations and the pathogenesis of multiple myeloma.
Proc. IIIrd Int. Myeloma Workshop, 15-17, 1991.
48
177. Grogan T, Durie BGM, Scheper R, Dalton B: Altered Cell Adhesion Molecule (CAM)
Expression Associated with Tumorgenicity in Plasma Cell Myeloma. Proc. IIIrd Int.
Myeloma Workshop, 77, 1991.
178. Samson D, Bird J, Newland AC, Joyner M, Durie BGM: A Randomized study
comparing VAP and Concurrent Interferon with VAD Followed by IFN Maintenance as
First Line Therapy in Newly Diagnosed Myeloma: Preliminary Results. Proc. IIIrd Int.
Myeloma Workshop, 100-102, 1991.
179. Durie BGM: Is magnitude of initial response predictive for survival in multiple
myeloma? Annals of Oncology, 2:167, 1991.
180. Bataille R, Boccadoro M, Klein B, Durie BGM, Pileri A: C-Reactive Protein and B2 Microglobulin Allow a Simple and Powerful Myeloma Staging System. Blood,1992.
181. Durie BGM, Crowley J, Coltman C, Chapman R, Balcerzak S, Bonnet J,
Lipschitz D, Stephens R, Cheson B: Phase II evaluation of bisantrene in refractory
multiple myeloma, a Southwest Oncology group study. Invest. New Drugs; 1991.
182. Durie BGM: The biology of interleukin 6: The role in plasma cell diseases.. Annals of
Oncology, 2:2:208-209, 1991.
183. Durie BGM, Vela EE, Baum V, Frutiger Y: Cytogenetics in multiple myeloma: a
review of findings in 130 patients. Proceedings B Cell Neoplasia, 7:161-172, 1991.
184. Durie BGM: What is Multiple Myeloma? Myeloma Today. Volume 1, Number 1, Pages
1-3, 1992.
185. Durie BGM: The Role of Transplantation in Multiple Myeloma. Myeloma Today.
Volume 1, Number 3, Pages 1-3, 1993.
186. Durie BGM: What causes Myeloma? Myeloma Today, Volume 1, Number 5, Page 1,
1993.
187. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE:
Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to
separate monoclonal gammopathy from multiple myeloma. Brit J Haematol, 83:63-67,
1993.
188. Rodriguez MA, Durie BGM, Richter L, Hicks MJ, Grogan TM: Immunohistologic studies
of bone marrow accessory cell populations in patients with multiple myeloma:
Correlations with prognostic parameters. Leukemia, 16:199, 1993.
189. Durie BGM: What causes myeloma: analysis of IMF database. Proc. Int. Myeloma
Symp., 10:432, 1994.
190. Huestis DW, Rifkin RF, Durie BGM, Sibley WA, Irani M: An unexpected complication
following immunoabsorption with a staphylococcal protein A column. A.J. Neuro,
79:119, 1994.
49
191. Durie BGM: What’s New in Myeloma Research. Myeloma Today, Volume 1, Number
9, Page 3, 1994.
192. Durie BGM: Inserm - Proceedings of Multiple Myeloma, From Biology to Therapy Current Concepts. 24-26 Octobre 1994 - Mulhouse, France.
193. Durie BGM: Bone disease in myeloma. Myeloma Today, Volume 1, Number 6, pages 34, 1994.
194. Mills D, Durie BGM, Grogan TM, Vela EE, Frutiger Y: Expansion of tumor infiltrating
lymphocytes with cytotoxic activity (early CD8+, CD11b- and late CD3+, CD56+ ) from
multiple myeloma bone marrow using IL-2 and LAK supernatant. Int. J. Immunol,
44:109, 1995.
195. Hagin G, Durie BGM: Idiopathic thrombocytopenic purpura: A review of the Arizona
experience. Arizona Medical Journal, 21:6, 1995.
196. Durie BGM: What’s New - Myeloma Specific Immune Transfer. Myeloma Today,
Volume 1, Number 10, 1995.
197. Modiano MR, Durie BGM, Seeger JF: Magnetic resonance imaging in myeloma: A
promising tool for diagnosis, staging and follow up. Ariz. Med J. 23:14. 1996.
198. Durie BGM: What’s New - Review of Recent Research. Myeloma Today Volume 2,
Number 1, 1996.
199. Durie BGM: Inserm Proceedings - The Biology of Multiple Myeloma, Brian G.M. Durie,
M.D., Scientific Director, International Myeloma Foundation (IMF), Los Angeles, CA
90046.
200. Durie BGM: Myeloma - 30 Years Forward Where to Now? Proceedings Arosa Myeloma
Meeting, January 31, 1996.
201. Durie BGM: Role of PSSC: 833 In Reversing Multi-drug Resistance in Myeloma
Proceedings Denver Myeloma Mtg., May 1996.
202. Durie BGM, Gale PR, Horowitz M: IBMTR Experience with Allogenic Transplantation
for Multiple Myeloma, PROC. Ann. Symp. 1996.
203. Durie BGM, Gale PR, Horowitz M: IBMTR Twin Transplant Results, PROC Ann. Symp.
1996.
204. Durie BGM, Vela EE, Knight I, Giles F: Significance of serum IL-6 levels in myeloma
and MGUS: An analysis in 136 patients. Europ. Journal of Clin. Onc. 32:364. 1996.
205. Durie BGM, Mason DY, Giles F, Vela EE, Knight I, Wolff S, Foadi M, Samson D:
Expression of BCL-2 oncogene protein in multiple myeloma. B. J. Onc. 14:319 1996.
50
206. Durie BGM: et al. Combined single cell testing for growth fraction (L1%) and Bcl-2
oncoprotein in myeloma. Leukemia Research. 13:114, 1997.
207. Durie BGM, Waxman A: Clinical Utility of MIBI Bone Scanning in Myeloma. PROC. Int.
Myeloma Workshop, 1997.
208. Ludwig H, Fritz E, Nueda J, Durie BGM: Patient preferences for Interferon alpha in
multiple myeloma. J. Clin. Onc. 15:1672,1997.
209. Durie BGM, Waxman A: FDG/PET scanning in multiple myeloma. PROC. Int. Soc Nuc
Med. 4:111, 1997.
210. Gale RP, Durie BGM: Delphi-panel analysis of appropriateness of high dose therapy
and bone marrow autotransplants in newly diagnosed multiple myeloma. Leukemia and
Lymphoma. 48:119, 1998.
211. Durie BGM, Urnovitz H: Expression of DU ALU RNA in the plasma of patients with
active myeloma. Leukemia. 46: 13-17, 1998
212. Durie BGM, Urnovitz H: Biaxin (Clarithromycin) as treatment for multiple myeloma.
PROC. Chemo. Found. Symposium. New York. XVI: 88-89, 1998.
213. Durie BGM, Urnovitz H: Active ALU sequences and the evolution of myeloma. Nat.
Genetics, 4: 111, 1998.
214. Durie BGM, Martin J: Stealth viruses and active myeloma: clinical correlations. Lancet,
Vol: 131-134, 1998.
215. Durie BGM, Damiano ML, Corrigan J, Volz R: Use of autoplex for successful bilateral
knee replacement in a hemophiliac with high tire inhibitor. Med Ped Onc. 4: 113-116,
1998.
216. Durie BGM: A role for complementary medicine in myeloma care. Myeloma Today. Vol
3, No 1: 3-4, 1998.
217. Gillespie TJ, Durie BGM, Garewal H, Davis TP: Analysis of D-Arabitonol, an indicator of
invasive candidiasis in leukemia patients, by gas chromatography/mass spectrometry.
Pharmacology. 6: 206-210, 1998.
218. Rodriguez MA, Meltzer PS, Durie BGM: Presence of Epstein-Barr virus in plasma cells
of human multiple myeloma. Onc Res. 16: 11-15, 1998.
219. Durie BGM, Rodriquez MA: Predictors of long term relapse free survival in multiple
myeloma. Acta Haemat. 38: 101-106, 1998.
220. Durie BGM, Bataille R: What causes myeloma? Proc Myeloma Symp. Nantes, France.
September 1-6, 1998.
221. Durie BGM: Thalidomide: Is it for you? Myeloma Today. Vol 3, No 3: 5-6, 1998.
51
222. Croghan M, Durie BGM, Dalton W, Vela E, Tu F: Paradoxic increased sensitivity of
chemotherapy-resistant myeloma cells to biologic agents and corticosteroids. J Clin
Pharm. 31: 46-49, 1998.
223. Meltzer P, Shadle K, Durie BGM: Somatic mutation alters a critical region of the C-MYC
gene in multiple myeloma. Canc. Res. 57: 107, 1998.
224. Durie BGM: Steroids: Why we love them, hate them, need them. Myeloma Today. Vol 3,
No 4: 7-8, 1999.
225. Durie BGM: What is STAT 3: Is it important? Myeloma Today. Vol 3, No 4: 8, 1999.
226. Durie B, Urnovitz J. Cell and molecular biology of simian virus 40: Implications for
human infections and disease. J Nat Ca Instut. 91(13):1166-1167, 1999.
227. Durie BGM: Tour de France Victory: Can it become a Tour de Force? Myeloma Today.
Vol 3, No 6: 3, 1999.
228. Durie BGM: What’s new on the horizon for myeloma? Myeloma Today. Vol 3, No 7: 5,
1999.
229. Durie BGM, Urnovitz HB, Murphy WH: RT-PCR amplicons in the plasma of multiple
myeloma patients, clinical relevance and molecular pathology. Acta Oncologica. 39
(No. 7): 789-796, 2000.
230. Durie BGM: Multiple myeloma: sliding scale
recommendations. Onc Economics, 8: 15-16, 2000.
therapeutics:
prescriptions
and
231. Durie BGM, Stepan DE: Efficacy of low dose thalidomise in multiple myeloma. Elec J
Onc, 2000, 1, 1-8. Available at www. Elecjoncol.org/ejo/cgi-bin/Escripts2000.pl
232. Durie BGM: The real world costs of multiple myeloma. Onc Spec, Vol 2, No 3: 86-93,
2001.
233. Durie BGM: Myeloma in the millennium: Outcomes of the IMF myeloma think tank 2000.
Myeloma Today, Vol 4, No 3: 1-3, 2001.
234. Durie BGM: Multiple myeloma: What’s new?. CA Cancer J Clin, 2001; 51: 271-272.
235. Durie BGM: Myeloma: What’s new? Myeloma Today, Vol 4, No 3: 6, 2001.
236. Durie BGM: Seventh International Myeloma Workshop: Meeting report from Banff,
Canada. May 4th-8th, 2001. Myeloma Today, Vol 4, No 5: 1-3, 2001.
237. Durie, BGM: Proceedings of the First International Myeloma Symposium.
Petersburg, Russia. Myeloma Today, Vol 4, No 5: 7-9, 2001.
52
St.
238. Durie BGM: Drug interactions with citrus fruits. Myeloma Today, Vol 4, No 7: 5, 2001.
239. Durie BGM: The epidemiology of multiple myeloma. Seminars in Hematology, Vol 38,
No 2, Suppl 3: 1-5, 2001.
240. Durie BGM: Thalidomide: clinical outcomes. VIIIth International Myeloma Workshop,
Banff, Canada, 2001.
241. Durie BGM: Cellular genetics of myeloma. Proc Int Myeloma Symp, Istanbul, Turkey.
June 2001, 1: 11-13.
242. Durie BGM: Advances in treatment of multiple myeloma. Aust Med J, 17: 104-110,
2001.
243. Durie BGM: International myeloma grand round. Lancet Oncology, Sept 2001.
244. Durie BGM: Deep in the bone, managing multiple myeloma. Cure, Vol 1, No 2, 2002.
245. Durie BGM: ASH 2001. Myeloma Today, Vol 4, No 8: 1-3, 2002.
246. Durie BGM: The “Myeloma Matrix”. Myeloma Today, Vol 4, No 9: 1, 2002.
247. Durie BGM: Infection in myeloma. Myeloma Today, Vol 4, No 9: 3, 2002.
248. Durie BGM: The importance of knowing the potential outcome. Myeloma Today. Vol 4,
No 10: 1-3, 2002.
249. Durie BGM: Outcomes of the IMF St. John’s retreat: Myeloma management guidelines.
Myeloma Today, Vol 5, No 1: 1-3, 2002.
250. Greipp PR, San Miguel JF, Durie BGM: Development of an international prognostic
index (IPI) for myeloma: report of the international myeloma working group. The Hem J,
Vol 4, Suppl 1: 71, 2003.
251. Durie BGM, Katz MS: Interactive computer program reveals current disease features
and patterns of myeloma management. The Hem J, 4, Suppl 1: 211, 2003.
252. Durie BGM, Gabayan E, Stepan DE: Low dose thalidomide plus dexamethasone
schedules produce equivalent results with less toxicity than higher doses in both
frontline and relapse myeloma. The Hem J, 4, Suppl 1: 325, 2003.
253. Supreme Court of the United States Amici Curiae Brief: Dow Chemical Company,
Monsanto Company, et al, petitioners, v. Stephenson, Isaacson, respondents. Brief
Amici Curiae of the Lymphoma Foundation of America, Cranor CF, Davis D, Defur PL,
Durie BG, Lockwood AH, Ozonoff D, Schecter AJ, and Wallinga D, in support of
respondents. No. 02-271. Submitted and published May 2003.
53
254. Durie BGM, Waxman AD, D’Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in
multiple myeloma. J Nucl Med, 44: 632-634, 2003.
255. Kumar A, Loughran T, Alsina M, Durie BGM. Management of multiple myeloma: a
systematic review and critical appraisal of published studies. .Lancet Oncology, 4: 293304, 2003.
256. Durie BGM: Low-dose thalidomide in myeloma: efficacy and biologic significance.
Seminars in Oncology, 29 (No 6, Suppl 17): 34-38, 2002.
257. Durie BGM, Waxman AD, D’Agnolo A, Williams CM: Whole-body 18F-FDG PET
identifies high-risk myeloma. J Nucl Med 2002; 43: 1457-1463.
258. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and
related disorders: a report of the International Myeloma Working Group. Br J Haematol,
121: 749-757, 2003.
259. Jacobson J, Huseein MA, Durie BGM, et al: A new staging system for multiple myeloma
patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol.,
122: 441-450, 2003.
260. Durie BGM, Kyle R, Bensinger W, et al: Myeloma Management Guidelines, a
consensus report from the scientific advisors of the International Myeloma Foundation.,
Haematology Journal, Vol 4: 379-398, 2003.
261. Durie BGM. Monitoring Multiple Myeloma with FDG/PET. Radiology Today, 4 (No. 2):
20-23, 2003.
262. Durie BGM: Multiple myeloma, cancer of the bone marrow. IMF Concise Review of the
disease and treatment options. 2004 Edition.
263. Durie BGM, Jacobson J, Barlogie B, et al. Time to progression, but not magnitude of
regression predicts survival benefit in SWOG standard dose chemotherapy studies for
multiple myeloma. J. Clin Onc, 22: 1857-1963, 2004.
264. Greipp PR, San Miguel J, Durie BGM, et al. An International Staging System for
Multiple Myeloma. J. Clin Onc, 23 (15): 3412-3420, 2005.
265. Jagannath S, Durie BGM, Wolf J, et al. Bortezomib therapy alone and in combination
with dexamethasone for previously untreated symptomatic multiple myeloma. Brit J
Haem, 129:776-783, 2005.
266. Durie BGM, Katz M, McCoy J, et al: Osteonecrosis of the jaw and bisphosphonates.
New Eng. J. Med, Jul 7, 353(1): 99-102, 2005.
267. Durie BGM. New Approaches to Treatment for Multiple Myeloma: Durable Remission
and Quality of Life as Primary Goals. Clin Lymphoma Myeloma, 6 (3): 181-90, 2005.
54
268. Durie BGM, Harousseau JL, et al. International uniform response criteria for multiple
myeloma. Leukemia, 20:1467-1473, 2006.
269. Durie BGM. The role of anatomic staging in myeloma: Description of Durie/ Salmon plus
staging system. European Journal of Cancer, 42 (11): 1539-43, 2006.
270. Barlogie B, Kyle RA, Durie BGM, et al. Standard chemotherapy compared with highdose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup
Trial S9321. JCO, Feb 20: 929-936, 2006.
271. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly
diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of
aspirin prophylaxis. Blood, 108(1): 403, 2006.
272. Durie BG, Attal M, Beksac M, et al. Use of bisphosphonates in multiple myeloma: IMWG
response to Mayo Clinic consensus statement. Mayo Clin Pro, 82:516-522, 2007.
273. Spisek R, Kukreja A, Chen L, Durie B, et al. Frequent and specific immunity to the
embryonal stem cell associated antigen SOX2 in patients with monoclonal
gammopathy. J Experimental Med, 204(4): 831-840, 2007.
274. Durie BGM. Novel approaches to myeloma therapy: The role of newer Anthracyclinecontaining regimens. Clin Lymph & Myeloma, 7(S4):S138, 2007.
275. Durie BGM, Rajkumar SV. (Letter to Editor) Assessing response rates in clinical trials of
treatment for relapsed or refractory multiple myeloma: a study of bortezomib and
thalidomide by H Prince, Brad Schenkel and Linda Mileshkin. Leukemia, 21:821, 2007.
276. Durie BGM. The importance of the new international uniform response criteria for
multiple myeloma. Am J Hemat Oncol, 6(5)S7:15-18, 2007.
277. Durie BGM. Baseline serum free light chain testing provides important prognostic data
in multiple myeloma. The Binding Site: Freelite Update, 1(2):1-3, 2007.
278. Stadtmauer EA, Lonial S, Vesole DH, et al. A practice guide to achieving and
maintaining the best response to lenalidomide in multiple myeloma: roundtable
proceeding. Clin Adv Hematol Oncol, 5(10 S15):7-19.
279. Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug
approvals for myeloma. Leukemia 22:231-239, 2008.
280. Hungria VTM, Maiolino A, Martinez G, et al. Confirmation of the utility of the
International Staging System and identification of a unique pattern of disease in
Brazilian patients with multiple myeloma. Haematologica, 93(5):791-792, 2008.
281. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and
lenalidomide-associated thrombosis in myeloma. Leukemia, 22:414-423, 2008.
55
282. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients younger than age 50
years presents with more favorable features and shows better survival: an analysis of
10 549 patients from the International Myeloma Working Group. Blood, 111:4039-4047,
2008.
283. Durie BGM. (Editorial) Oncology nurses take the lead in providing novel therapy
guidelines for multiple myeloma. Clin J Oncol Nurs 12(3)S:7-8, 2008.
284. Rajkumar SV, Durie BGM. Eliminating the complete response penalty from myeloma
response criteria. Blood, 111(12):5759, 2008.
285. Hussein MA, Vrionis FD, Allison R, et al. The role of vertebral augmentation in multiple
myeloma: International myeloma working group consensus statement. Leukemia
advance online publication; doi:10.1038/leu.2008.127, May 29, 2008.
SUBMITTED OR IN PRESS
286. Hussein M, Bolejack V, Zonder J, Durie B, et al. Phase II study of thalidomide plus
dexamethasone induction followed by tandem melphalan-based autotransplantation and
thalidomide-prednisone maintenance for untreated multiple myeloma: a Southwest
Oncology Group trial (S0204). Blood, Submitted July 2008.
287. Ludwig H, Anderson KC, Dammacco F, et al. ESAs not the culprit: More studies
required. Am J Hemat Oncol, In Press, August 2008.
288. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood
of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high
risk gene signatures. Leukemia, Submitted, August 2008.
289. Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design,
content, and initial application of the Bank on a Cure SNP panel to analysis of survival.
BMC Medical Genet, In Press, August 2008.
290. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide
mediated venous thrombotic events in myeloma identified using targeted genotyping,
Blood, In Press, 2008.
291. Durie BGM. (Editorial) Treatment of myeloma- Are we making progress?. New Engl J
Med, In Press, August 2008.
292. Zonder JA, Crowley J, Hussein MA, et al. S0232: Dex +/- lenalidomide for previously
untreated myeloma- updated results. Blood, Submitted, 2008.
293. Durie BGM. (Commentary) Crossover confusion: MPT still best. Blood, In Press,
September 2008.
56
294. Durie BGM.(Commentary) Myeloma therapy: 25 years forward- Immune modulation
then and now. J Clin Oncol, In Press, October 2008.
295. Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines
for serum free light chain analysis in multiple myeloma and related disorders. Leukemia,
Submitted, 2008.
296. Kyle RA, Boccadoro M, Rajkumar SV, Durie BGM. Monoclonal gammopathy of
undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma:
Risk factors for progression. In Preparation, 2008.
297. Giralt S, Harousseau JL, Palumbo A, et al. International myeloma working group
consensus statement on the role of plerixafor in stem cell harvesting. In Preparation,
2008.
298. Fonseca R, Avet-Loiseau H, et al. International myeloma working group genetic
classification of myeloma. In Preparation, 2008.
299. Kumar S, et al. International myeloma working group consensus statement on the risk
factors for stem cell harvesting in myeloma. In Preparation, 2008.
300. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma long term survival: Calculation of
potential life-years lost: An analysis of 10,549 patients from the International Myeloma
Working Group. In Preparation, 2008.
301. Jagannath S, Durie BGM, et al. Long-term follow up of patients treated with bortezomib
alone and in combination with dexamethasone as frontline therapy for multiple
myeloma: Impact of initial autologous stem cell transplantation, In Preparation, 2008.
302. Durie BGM, Urnovitz H, et al. Circulating nucleic acids in multiple myeloma: presence
of non-coding/intergenic DNA reflects disease activity. In Preparation, 2008.
CHAPTERS
1.
Durie BGM: Therapy of multiple myeloma. In: Current Therapy (Ed. By HF
Saunders Co., Philadelphia, 326-328, 1978.
2.
Durie BGM, Russell DH: Polyamines as tumor markers. In: Tumor Markers: Impact and
Prospects, Elsevier/North Holland Biomedical Preast 1979.
3.
Durie BGM: Kinetic studies in myeloma and their implications for treatment. In:
Principles of Cancer Treatment, Ed. by Carter SK, Glatstain E, Livingstone RB.
McGraww-Hill Book Co., 1980.
4.
Durie BGM: Polyamines and cancer therapy. In: Polyamines in Biomedical Research.
Ed. by JM Caugus, John Wiley & Sons LTD, 1980.
57
Conn), WB
5.
Durie BGM: Cell kinetic analysis of human tumor stem cells. In: Chapter 13: Cloning of
Human Tumor Stem Cells, Alan R Liss, Inc., New York, pp l53-163, 1980.
6.
Durie BGM: Multiple myeloma. Current concepts in the use of Doxorubicin
Chemotherapy, Farmitalia, Ed. Stephen Jones, 95-101,1982.
7.
Durie BGM: Acute and chronic leukemia. Current Concepts in the use of Doxorubicin
Chemotherapy, Farmitalia, Ed.Stephen Jones, 87-94, 1982.
8.
Durie BGM: Thyroid carcinoma. Current concepts in the use of Doxorubicin
Chemotherapy, Farmitalia, Ed. Stephen Jones, 117-120, 1982.
9.
Durie BGM: Chemotherapy of multiple myeloma Bailliere’s Clinical Haematology, Vol. 4,
No. 1:181-195, January 1991.
10.
Durie BGM: Cellular and Molecular Genetic Features of Myeloma and Related
Disorders. Hematology/Oncology Clinics of North America, Vol. 6, No. 2, April 1992.
11.
Durie BGM: Myeloma and Other Paraproteinemias. Oxford Textbook of Medicine. Vol.
1 3rd Edition 1996.
12.
Durie BGM: Epidemiology of Myeloma. Butterworth Press. 1997.
13.
Durie BGM: Basic Biology and Treatment of Multiple Myeloma.
Haematology. 1997.
14.
Durie BGM: The role of imaging in multiple myeloma. Arnold Press, 155-163, 2004.
15.
Durie BGM: Epidemiology of multiple myeloma and related disorders. Humana Press,
13-26, 2004.
16.
Durie BGM: The role of imaging in multiple myeloma. Springer Publishing, 2008.
Postgraduate
BOOKS
1.
Russell DH, Durie BGM: Polyamines as Biochemical Markers of Normal and Malignant
Growth. Progress in Cancer Research and Therapy,, 8. Raven Press 1978.
2.
Durie BGM: Multiple Myeloma: Concise Review (6 languages). International Myeloma
Foundation Press 1993. New edition published 1998.
3.
Durie BGM: Multiple Myeloma: Patient Handbook (6 languages). International
Myeloma Foundation Press 1994.
4.
Gharton G and Durie BGM: Multiple Myeloma. First edition. Arnold Press. 1996.
5.
Gharton G, Durie BGM, Samson D. Multiple Myeloma and Related Disorders. 2nd
Edition. Arnold Press. 2004.
58
VIDEOCASSETTES
1.
Durie BGM, Redding KE: Bone marrow transplantation: One patient's experience. Video
Cassette: Biomedical Communications, University of Arizona, 1983.
2.
Durie BGM, Redding KE: Bone marrow transplantation: A donor's experience. Video
Cassette: Biomedical Communications University of Arizona 1983.
3.
Durie BGM, Redding KE: Bone marrow transplantation in acute leukemia.
Cassette: Biomedical Communications, University of Arizona, 1983.
Video
PUBLISHED ABSTRACTS
1.
Durie BGM, Taswell HF: Mixed leukocyte culture in patients with myelomonacytic
leukeumia. Abstract No. 324, p. 14l, American Society of Hematology Fifteenth Annual
Meeting, Hollywood, Florida, Dec. 3-6, 1972.
2.
Salmon SE, Durie BGM: Kinetics of tumor cell growth in immunoproliferative disorders.
Proceedings of the International Society of Hematology, September, 1974.
3.
Jones SE, Lilien KL, O’Mara RE, Salmon SE, Durie BGM: Solid tumor scanning with
indium-bleomycine. Proceedings of the American Association Cancer Research p9O,
1974.
4.
Lilian DL, Jones SE, O’Mara RE, Salmon SE, Durie BGM: A clinical evaluation of
indium-bleomycin an a tumor imaging agent. (Abstract). Journal of Nuclear
Medicine 15:512, 1974.
5.
Salmon SE, Durie BGM: Critical role of temperature in high speed scintillation
autoradiography (HSARG). CLIN RES. 23:406A, 1975.
6.
Durie BGM, Hellman D, O'Mara R, Woolfenden J, Kartchner M, Salmon SE:
Multimodality treatment for high risk thyroid carcinoma. ASCO 17:Cl62, 1976.
7.
Rosenblum MG, Durie BGM, Salmon SE, Chang S, Russell DH: A spermidine
conjugate in body fluids of rats and humans. AACR 17:60, 1976.
8.
Meezen E, Cole PW, Durie BGM, Salmon SE, Brendal K: Inhibition of Paminohippurate
transport in isolated rabbit renal tubules Bence Jones protein, Fed Proc 35:2143, 1976.
9.
Cole PW,, Salmon SE, Durie BGM: Quantitative radial imunodiffusion of free light chain
immunoglobulins in myeloma patients. Fed Proc 35:377, 1976.
59
10.
Durie BGM, Vaught L, Russell DH, Salmon SE: Dynamic Relationship of Cytokineties to
tumor burden and response to treatment in multiple myeloma. American Society of
Hematology, 19th Annual Meeting, Boston, Mass., 128: 225, December 1976.
11.
Durie BGM, Payne C, Kim HD, Fletcher J, Watts RB, Edholm J, Luthra M, Hanahan DJ:
Detailed studies of unusual membrane abnormalities in a family with congenital
dyserythropoietic anemia (CDA) type 1. American Society of Hematology, 19th Annual
Meeting, Boston, Mass., 57:13, December 1976.
12.
Durie BGM, Vaught L, Salmon SE: Prognostic significance of tritiated thymidine labeling
index (LI) in multiple myeloma and acute myeloid leukemia.
Proc. 68th Annual
Meeting American Association for Cancer Research, Denver, Colorado, 80:320, May
1977.
13.
Rosenblum MG. Durie BGM, Salmon SE, Russell DH: Pharmacokinetics of 14Cputrescine and 14Cspermidine in patients with cancer. Proc 68th Annual Meeting
American Association for Cancer Research, Denver, Colorado, 80:320, May 1977.
14.
Durie BGM, Salmon SE, Russell DH: Comparison clinical utility of plasma and urine
polyamine determinations in cancer chemotherapy Proc 13th Annual Meeting American
Society of Clinical Oncology, Denver, Colorado, 295:C-115, May 1977.
15.
Eisenberg AC, Durie BGM, Huestis, DW: Prognostic factors and toxicity in patients
receiving therapeutic and prophylactic granulocyte transfusions. American Society of
Hematology, San Diego,
California, Abstract 638, December 3-5, 1977.
16.
Cole PW, Himmelstein KJ, Salmon SE, Durie BGM: Light chain imrnunoglobulin
metabolic studies and the calculation of total tumor burden in Bence Jones myeloma
patients. Fed Proc 37:1763, 1978.
17.
Salmon SE, Soehanlen BJ, Durie BGM, Alberts DS, Meyskens FL, Chen H-SG, Moon
TE: Clinical correlations of drug sensitivity in tumor stem cell assay. American Society of
Clinical Oncology, May 1979.
18.
Durie BGM, Young LA, Salmon SE: Clinical importance of kinetics in myeloma stem call
cultures. American Society of Clinical Oncology, May 1979.
19.
Salmon S, Buick RN, Soehnlen BA, Trent JM Durie BGM, Alberts DS, Meyskens L:
Human tumor cloning in vitro: Insights on biology kinetics and prediction of response to
treatment. Abstract. Xth Meeting European Study group for the cell Proliferation.
20.
Voakes J, Durie BGM, Levine A, Jett J, Levy h, Salmon S: Poly (ICLC) as an interferon
inducer in refractory multiple myeloma. American Association of Cancer Research,
198.
21.
Salmon S, Alberts D, Meyskens F, Durie BGM, Jones S, Soehnlen B, Young L: A new
concept: In vitro phase II trial with the human tumor stem call assay. American Society
of Clinical Oncology 1980.
60
22.
Ahmann F, Meyskens F, Jones S, Durie BGM, Alberts D. Salmon S: A broad phase II
trial of AMSA with in vitro stem cell culture drug sensitivity American Association of
Cancer Research, 1980.
23.
Durie BGM, Salmon S: The kappa and lambda survival differences in multiple myeloma.
Evidence for a biologic basis. American Society of Clinical Oncology, 1980.
24.
Durie BGM: Recent advances in multiple myeloma. Swiss Society Hematology, Zurich,
Switzerland, 1980.
25.
Durie BGM: Cloning efficiency and monitoring of the chemotherapy of plasma cell
myeloma. Ettore Majorana, Centre for Scientific Culture. International School of Medical
Sciences. Advances in Lymphoproliferative Disorders. 15th course, 309-319, 1981.
26.
Moon T, Salmon S, Alberts D, Chen G, Durie BGM, Meyskens F: Quantitative analysis
of the human tumor stem call assay (HTSCA) and the degree of association with clinical
response. Proceedings, Seventeenth annual meeting of the American Society of Clinical
Oncology (ASCO), 2/C- 61:348, 1981.
27.
Herman TS, Durie BGM, Hutter J: Treatment of refractory acute myelogenous leukemia
(AML) with vincristine, high dose methotrexate, 1 3-BIS-(2-Chlorethy)-1-Nitrosourea
(BCNU), Cyclosphosphide, and Methyl-Gloyoxal BIS-Guanylhydrazone (MGBG).
Proceedings, Seventeenth annual meeting of the American Society of Clinical Oncology
(ASCO), 22/c-559 476, 1981.
28.
Durie BGM. Norris-Kloos L, Soehnlen B, Trnet JM: Cytogenetic analysis of clonogenic
human acute myeloid leukemia (AML) and multiple myeloma (MM) cells. Proceedings,
72nd Annual Meeting of the American Association for Cancer Research (AACR),
22/600:151, 1981.
29.
Hofmann V, Salmon SE, Durie BGM: Drug resistance in multiple myeloma associated
with high in vitro incorporation of 3H-thymidine (TdR). Seventeenth Annual Meeting of
the American Society of Clinical Oncology (ASCO), 22/C-794:536, 1981.
30.
Salmon SE, Buick RN, Seohnlen B, Trent J, Durie BGM, Alberts D, Meyskens F:
Human Tumor cloning in vitro: Insights an biology, kinetics, and prediction of response
to treatment. Xth Meeting European Study Group for Cell Proliferation. Cell and Tissue
Kinetics, 1981.
31.
Hicks MJ, Layton JM, Ludwig C, Durie BGM, Powell M, Tabing T: Sex related
differences in T cell subpopulations and the importance of sex-matched controls,
Laboratory Investigation, 46:36A, 1982.
32.
Durie BGM, Vaught L, Soehnlen B, Salmon SE: Sensitivity to interferons and bisantrene
in refractory multiple myeloma: Comparison between thymidine suppression, myeloma
stem cell culture, and clinical results. American Association for Cancer Research
(AACR), April, 1982.
61
33.
Dana BW, Durie BGM, Whie RF, Huestis DW, Paplanus S: Fungal infections in patients
receiving granulocyte transfusions: Clinical course and risk factors, Western Section,
AFCB, 1982.
34.
Durie BGM, Ludwig CL: Smoldering myeloma: A analysis of patients developing overt
disease. American Society of Hematology (ASH), in Blood, no. 5Ol, 6O (5):l43a. 1982.
35.
Bataille R, Durie BGM, Grenier J: Prognostic value of serum beta-2-microglobulin (S2M) in multiple myeloma (MM): A prospective study of 107 patients. American Society of
Hematology (ASH), Blood, no. 499, 60(5):143a, 1982.
36.
Villar HV, Dunnington GL, Ranne RD, Durie BGM, Jones SE, Grogan TM: Hairy cell
leukemia. The role of splenectomy. (Abst). Society of University Surgeons-45th Annual
Meeting, February, 1984.
37.
Durie BGM, Christiansen JA, Vela EE: Recent observations on enhanced cloning of
multiple myeloma in vitro. Fourth conference on Human Tumor Cloning, Tucson
Arizona. January, 1984
38.
Garewal H, Durie BGM: High dose cytosine arabinoside, dacuomycin and Gthiaguanine in replaced acute myelogenous leukemia. Clinical Res. 32:24a, 1984.
39.
Garewal H, Corrigan JJ, Durie BGM, et al: Effects of danazol on APTT, coagulant factor
activity and bleeding in hemophilia. American Pediatric Society, 1984.
40.
Berdeaux D, Glasser L, Serokman R, et al: Hypoplastic acute leukemia: Review of 70
cases. Blood 64 (5, suppl. 1): 145a, 1984.
41.
Bataille R, Durie BGM, Grenier J: Prognostic factors and staging in multiple myeloma
(MM): A re-appraisal, evaluating new parameters. Blood 64 (5, suppl. 1): 152a, 1984.
42.
Durie BGM, Vela E, Vaum V, et al: Establishment of two new human myeloma cell lines
from bilateral pleural effusions: Evidence for sequential clonal change. Blood 64 (5,
suppl 1): 188a, 1984.
43.
Villar HV, Peck ME, Hunter TB, et al: Gastrointestinal complications in leukemia
patients. Society of Surgical Alimentary Tract, Vol. 31: 1143, 1984.
44.
Durie BGM, Vela E, Payne C: Recent observations of amyloid production in myeloma
colony culture. Ninth International Symposium of Amyloidosis, pg 90, November 9-12,
1984.
45.
Rodriguez MA, Durie BGM, Meltzer PS: Evidence that a subset of human myelomas
contain Epstein Barr Virus. J Clin Oncol, 4: 13(50), 1985.
46.
Durie BGM, Dixon DO, Carter S, et al: Improved survival duration with combination
chemotherapy induction for multiple myeloma. Am Soc Hematol, Abstract, Blood
(Suppl), 66: 2201, (766), 1986.
62
47.
Dalton WS, Durie BGM, Gerlach J, et al: Development and characterization of a new
drug resistant human multiple myeloma cell line. Am Soc Hematol, Abstract, Blood
(Suppl), 66: 220a, (766), 1986.
48.
Clouse L, Braich T, Grimm M, et al: A phase I trial of oral cyclophosphamide (CTX) and
subcutaneous recombinant alpha-2b-interferon (INF) in patients with malignant disease.
Proc. Am Soc Clin Oncol, 5 (Abstr): 229 (892), 1986.
49.
Dalton WS, Durie BGM, Grogan RM, et al: Cytogenetic and phenotypic analysis of a
drug resistant human myeloma cell line. Proc AARC 27: 271 (1074), 1986.
50.
Villar H, Dunnington G, Ranne R, et al: Hairy cell leukemia: the role of immunologic
markers and splenectomy. (Abstract) Presented at the 106th annual meeting of the
American Surgical Association, 1986.
51.
Durie BGM, Baum VE, Vela EE, et al: Abnormalities of chromosome 6q and osteoclast
activating factor (OAF; TNF-production in multiple myeloma. (abstract). Presented at
American Society Hematology, December 1986.
52.
Meltzer P, Shadle K., Durie BGM: Somatic mutation alters a critical region of the CMYC gene in multiple myeloma (abstract). The American Society of Hematology, 29th
annual meeting, Abst # 867, 1987.
53.
Buzaid A, Durie BGM: Prednisone: and effective agent in refractory myeloma. Abst #
103, Western AFCR, 1987.
54.
Meltzer PS, Shadle KM, Durie BGM: Characterization of a recurrent alterations of CMYC in multiple myeloma. ASCO, Abst # 719, 1987.
55.
Shadle KM, Meltzer PS, Durie BGM: Somatic mutation alters a critical region of the
MYC gene in multiple myeloma (abstract). Clinical Research Vol. 36, 1988.
56.
Buzaid AC, Durie BGM: Prednisone alone: an effective agent in refractory myeloma
(abstract). Clinical Research Vol 36, 1988.
57.
Durie BGM, Vela EE, Baum V. Cytogenetic abnormalities in multiple myeloma.
Proceedings of Mechanisms of B cell Neoplasia, 1990.
58.
Durie BGM, Vela EE, Frutiger Y. Macrophages as an important source of paracrine IL-6
in myeloma bone marrow. Proceedings of Mechanisms of a B cell neoplasia, 1990.
59.
Durie BGM, Mason Dy, Giles F, Vela EE, Knight I, Wolff S, Foadi M, Samson D.
Expression of the BCL-2 Oncogene Protein in Multiple Myeloma. Blood, Vol. 76, No. 10,
Sup. 1, P 347a, 1990.
60.
Giles FJ, Knight I, Vela EE, Jewell AP, Worman CP, Goldstone AH, Durie BGM. Serum
interleukin 6 levels in patients with multiple myeloma: effects of cytotoxic chemotherapy,
hemibody radiotherapy, BMT and alpha interferon. BSH, 1991 (Glasghow), submitted.
63
61.
Buckner CD, Clift R, Durie BGM, Appelbaum FA, Hansen JA, Bianco J, Singer J, Storb
R, Thomas ED. Allogenenic Marrow Transplantation for Multiple Myeloma Using
Busulphan and Cyclophosphamide. Blood, Vol 76, No. 10, Supp 1, P527a,1990.
62.
Durie BGM: The role of IL-6 in Myeloma. Annals of Oncology, Supp. 1 to Volume 3,
March 1992, p 163.
63.
Durie BGM: Role of Autologous and Allogenic Transplantations in Multiple Myeloma.
Proc. 1, BMTR Symp. Feb 1994.
64.
Durie BGM: Current Approaches to Myeloma Treatment.
October 1994.
65.
Durie BGM: The Demographics of Multiple Myeloma. Symposium Royal College of
Physicians. London Proceedings. May 1994.
66.
Durie BGM: Twin Transplants in Multiple Myeloma. Proc IBMTR Symp. February
1995.
67.
Durie BGM: Mechanisms and Treatment of Bone Disease in Myeloma.
Onc. Symp. Vienna, Austria. Sept 1996.
68.
Durie BGM: What Causes Myeloma: review and update. Proc. Cleveland Clinic Symp.
August 1996.
69.
Durie BGM: Current Concepts of Myeloma Pathogenesis.
Sydney, Australia. April 1997
70.
Durie BGM: Role of High-dose Therapy and Transplantation in Myeloma. PROC Alta
Bates Symp. Inn at Spanish Bay. September 1997.
71.
Durie BGM: Circulating DU-ALU Containing Sequence in Multiple Myeloma. Blood.
Nov Abst 1070. 1997. (ASH)
72.
Durie BGM: Clarithromycin as Treatment for Multiple Myeloma. Blood Nov Abst 2578.
1997. (ASH)
73.
Durie BGM: FDG/PET Whole Body Scanning for Multiple Myeloma. PROC INT SOC.
Nuc Med. Toronto, Canada. April 1998.
74.
Durie BGM: Standard Dose Chemotherapy for Myeloma. PROC. Royal College of
Physicians Symp. London. July 1998.
75.
Durie BGM: Role of Viruses and Retroviruses in the Pathogenesis of Myeloma. Swiss
Haem. Symp. Geneva, Switzerland. September 1998.
76.
Durie BGM: New Paradigms in the Management of Myeloma. Haem. Soc of Brazil.
Am. Symp. Proceedings Oct 1998.
64
Proc. Scripps Symp.
Proc. Europ.
Proc. Myeloma Symp.
77.
Durie BGM: Current Approaches to Myeloma. PROC. Scripps Cancer Symp. San
Diego. October 1998.
78.
Durie BGM, Martin J: Stealth Virus and active myeloma: clinical correlations. BLOOD.
94:10 Suppl 1. November 15, 1999. (ASH)
79.
Jacobson J, Hussein M, Barlogie B, Durie BGM, Crowley J: Beta 2 Microglobulin (B2M)
and Albumin Define a New Staging System for Multiple Myeloma: The Southwest
Oncology Group (SWOG) Experience. BLOOD. 98:11. November 16, 2001 Part 1.
(ASH)
80.
Durie BGM, Stepan D: Low Dose Thalidomide Alone and in Combination: Long Term
Follow-Up. BLOOD. 98:11. November 16, 2001 Part 1. (ASH)
81.
Durie BGM, Waxman A, D’Agnolo A: Prognostic Value of Whole Body FDG/PET
Scanning In Multiple Myeloma. BLOOD. 96:11. November 16, 2002 Part 1. (ASH)
82.
Durie BGM, Jacobson J, Barlogie B, Crowley J. Time to First Progression Is the Best
Predictor of Survival Duration in SWOG Standard Dose Chemotherapy Studies.
American Society of Hematology (ASH). December 2002.
83.
Durie BGM, Mundy GR. Statin Use and the Likelihood of Bone Disease in Newly
Diagnosed Myeloma: Abstract 5097. Blood, 100: 383b, 2002. (ASH)
84.
Jagannath S, Durie BGM, Wolf J, et al. Bortozemib (VELCADE™, Formerly PS-341) as
first-line therapy in patients with Multiple Myeloma: Abstract #1650. Blood, November
Supplement, 2003. (ASH)
85.
Jagannath S, Durie BGM, Wolf J, et al.
First-line therapy with Bortozemib
(VELCADE™, Formerly PS-341) in patients with Multiple Myeloma: Abstract #6551. J
Clin Onc, 23: 568, June 2004. (ASCO)
86.
Ludwig H, Durie BGM, Bolejack V, et al. Multiple myeloma (MM) in young patients
(pts): Clinical features and outcome in 259 patients younger than 40 years in
comparison to 8,296 pts aged 40 years: Abstract #3414. Blood, 106 (11), December
2005. (ASH)
87.
Hussein MA, McCoy J, Durie B, et al. SWOG 0204: Phase 2 trial of thalidomide (T) +
dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone
(P) + T maintenance for multiple myeloma (MM): Abstract #1169. Blood, 106 (11),
December 2005. (ASH)
88.
Dhodapkar MV, Zhan F, Durie B, et al. Gene expression profiling of bulk CD138+
plasma cells in preneoplastic gammopathy/ asymptomatic myeloma identifies distinct
subsets of patients. Abstract #1218. Blood, 106 (11), December 2005. (ASH)
65
89.
Johnson DC, Grindle J, Durie BGM, et al. Inherited genetic variation and the risk of
developing venous thrombosis with thalidomide treatment in myeloma patients.
Abstract #1624. Blood, 106 (11), December 2005. (ASH)
90.
Zonder JA, Durie BGM, et al. High incidence of thrombotic events observed in patients
receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple
myeloma (MM) without aspirin (ASA) prophylaxis. Abstract #3455. Blood, 106 (11),
December 2005. (ASH)
91.
Van Ness BG, Durie BGM, et al. SNP genotypes show association with common
toxicities during both VAD induction and high dose melphalan with autologous
transplant support in intergroup trial S3921 for myeloma: from the Bank on a Cure.
Abstract #3488. Blood, 106 (11), December 2005. (ASH)
92.
Van Ness B, Crowley J, Durie BGM, et al. SNP genotypes as prognostic factors
associated with staging in myeloma: the first combined SNP association analysis of
SWOG, ECOG, and MRC clinical trials from the Bank on a Cure. Abstract #3489.
Blood, 106 (11), December 2005. (ASH)
93.
Van Ness B, Crowley J, Durie BGM, et al. Incidence, outcomes, and SNP genotypes
show different ethnic association in patients with myeloma, assessed in SWOG and
ECOG clinical trials S9321 and E9486: from the Bank on a Cure. Abstract #506. Blood,
106 (11), December 2005. (ASH)
94.
Johnson DC, Grindle SM, Durie BGM, et al. Development of a panel of 3,500 SNP
based functional genetic variants relevant to the etiology and outcome in multiple
myeloma. Abstract #620. Blood, 106 (11), December 2005. (ASH)
95.
Jagannath S, Durie BGM, et al. Bortezomib therapy alone and in combination with
Dexamethasone for patients with previously untreated multiple myeloma. Absrtact
#783. Blood, 106 (11), December 2005. (ASH)
96.
Durie BGM, et al. Circulating Nucleic Acids in multiple myeloma: presence of noncoding/ intergenic DNA reflects disease activity. Abstract #5095. Blood, 106 (11),
December 2005. (ASH)
97.
Spisek R, Chen L-C, Durie BGM, et al. Differential antigenic targets of anti-tumor
immune response and selective immunity to stem cell associated group B SOX proteins
in preneoplastic versus malignant gammopathy. Abstract #5116. Blood, 106 (11),
December 2005. (ASH)
98.
Van Ness B, Crowley J, Durie BGM, et al. SNP associations with event free survival in
myeloma from two phase III clinical trials using the Bank on a Cure chip. Abstract #131.
Blood, 108(11), December 2006. (ASH)
99.
Jagannath S, Durie BGM, et al. Long-term follow-up of patients treated with bortezomib
alone and in combination with dexamethasone as frontline therapy for multiple
myeloma. Abstract #796. Blood, 108(11), December 2006. (ASH)
66
100. Morgan GJ, Johnson DC, Durie BGM, et al. The genetic contribution to the aetiology of
thalidomide associated VTE. Abstract #246. Blood, 108(11), December 2006. (ASH)
101. Durie BGM and Jones H. New bioaccumulations of toxins in resident coastal dolphins
signal dangers of human myeloma. Abstract #5062. Blood, 108(11), December 2006.
(ASH)
102. Durie BGM, et al. Deep vein thrombosis in myeloma: estimates of problem and
recommendations for therapy based upon a survey of members of the International
Myeloma Working Group. Abstract #3571. Blood, 108(11), December 2006. (ASH)
103. Bertolotti, P, Bilotti B, Durie BGM, et al. Nursing guidelines for enhanced patient care.
Presented Abstract for XIth IMW 2007.
104. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high
dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed
multiple myeloma (NDMM): Results of the randomized, double-blinded, placebocontrolled SWOG trial S0232. Abstract #77. Blood, 110(11), November 2007 (ASH).
105. Jagannath S, Bensinger B, Vescio R, et al. A phase II study of bortezomib
(VELCADE®), cyclophosphamide (Cytoxan®), thalidomide (Thalomid®)
and
dexamethasone as first-line therapy for multiple myeloma. Abstract #188. Blood.
110(11), November 2007 (ASH).
106. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood
of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high
risk gene signatures. Abstract # 816. Blood. 110(11), November 2007 (ASH).
107. Morgan GJ, Jenner MW, Walker BA, et al. An integrated pharmacogenomics strategy
for the definition of thalidomide response signatures in presenting cases of multiple
myeloma. Abstract #2493. Blood. 110(11), November 2007 (ASH).
108. Zonder JA, Crowley JJ, Bolejack V, et al. A randomized Southwest Oncology Group
study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as
treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic
abnormalities on efficacy of LD, and updated overall study results. Abstract #8521. J
Clin Oncol. 26(15S), 2008 (ASCO).
109. Durie B. Treatment of haematological malignancies: Durable remissions and quality of
life as primary goals. June 2008 (EHA).
67